JOSEPH JANKOVIC to Humans
This is a "connection" page, showing publications JOSEPH JANKOVIC has written about Humans.
Connection Strength
5.220
-
Botulinum Toxin for the Treatment of Tremors. Toxins (Basel). 2025 Aug 11; 17(8).
Score: 0.025
-
Functional Head Tremor: Contrasting Features with Other Tremor Etiologies. Mov Disord Clin Pract. 2025 Dec; 12(12):2289-2295.
Score: 0.025
-
Response to the letter "Reassessing the hypothesis of essential tremor as a prodromal feature of Parkinson's disease". Parkinsonism Relat Disord. 2025 Mar; 132:107280.
Score: 0.024
-
Drug-induced parkinsonism: diagnosis and treatment. Expert Opin Drug Saf. 2024 Dec; 23(12):1503-1513.
Score: 0.024
-
Axial tics in Tourette syndrome and chronic tic disorders. J Neurol. 2024 Nov; 271(11):7232-7238.
Score: 0.024
-
Does Delaying Levodopa Prevent Motor Complications in Parkinson's Disease? A Meta-Analysis. Mov Disord Clin Pract. 2024 Oct; 11(10):1195-1202.
Score: 0.024
-
Tapping the Brakes on New Parkinson Disease Biological Staging. JAMA Neurol. 2024 Aug 01; 81(8):789-790.
Score: 0.024
-
Treatment response to onabotulinumtoxinA in cervical dystonia patients with anterocollis and retrocollis. Toxicon. 2024 Sep; 248:108035.
Score: 0.024
-
Functional Neurological Disorders Among Patients With Tremor. J Neuropsychiatry Clin Neurosci. 2025; 37(1):61-66.
Score: 0.024
-
An update on the pharmacological management of Tourette syndrome and emerging treatment paradigms. Expert Rev Neurother. 2024 Oct; 24(10):1025-1033.
Score: 0.024
-
Medication refractory restless legs syndrome: Real-world experience. J Neurol Sci. 2024 Aug 15; 463:123121.
Score: 0.024
-
Leg stereotypy syndrome: phenomenological and quantitative analysis. J Neurol. 2024 Aug; 271(8):5519-5524.
Score: 0.024
-
Systemic Symptoms in Huntington's Disease: A Comprehensive Review. Mov Disord Clin Pract. 2024 May; 11(5):453-464.
Score: 0.023
-
Tics emergencies and malignant tourette syndrome: Assessment and management. Neurosci Biobehav Rev. 2024 Apr; 159:105609.
Score: 0.023
-
Is Dystonia an Immunologic Disorder? Parkinsonism Relat Disord. 2024 May; 122:106084.
Score: 0.023
-
Botulinum toxin treatment in parkinsonism. J Neurol Sci. 2024 01 15; 456:122810.
Score: 0.023
-
Linking the cerebellum to Parkinson disease: an update. Nat Rev Neurol. 2023 11; 19(11):645-654.
Score: 0.022
-
Treatment of cervical dystonia with Botox (onabotulinumtoxinA): Development, insights, and impact. Medicine (Baltimore). 2023 Jul 01; 102(S1):e32403.
Score: 0.022
-
Spinal cord stimulation for gait disturbances in Parkinson's disease. Expert Rev Neurother. 2023 Jul-Dec; 23(7):651-659.
Score: 0.022
-
Real-world experience with VMAT2 inhibitors in Tourette syndrome. J Neurol. 2023 Sep; 270(9):4518-4522.
Score: 0.022
-
Neutralizing Antibody Formation with OnabotulinumtoxinA (BOTOX?) Treatment from Global Registration Studies across Multiple Indications: A Meta-Analysis. Toxins (Basel). 2023 05 17; 15(5).
Score: 0.022
-
Contrasting features between Tourette syndrome and secondary tic disorders. J Neural Transm (Vienna). 2023 07; 130(7):931-936.
Score: 0.022
-
Peripherally-induced Movement Disorders: An Update. Tremor Other Hyperkinet Mov (N Y). 2023; 13:8.
Score: 0.022
-
Botulinum Neurotoxin Injections in Children with Self-Injurious Behaviors. Toxins (Basel). 2023 03 23; 15(4).
Score: 0.022
-
How should future clinical trials be designed in the search for disease-modifying therapies for Parkinson's disease? Expert Rev Neurother. 2023 02; 23(2):107-122.
Score: 0.021
-
Oromandibular tics associated with Tourette syndrome. J Neurol. 2023 May; 270(5):2591-2596.
Score: 0.021
-
Secondary dystonia following parenchymal brain tumors. J Neurol Sci. 2023 03 15; 446:120577.
Score: 0.021
-
Practical pearls to improve the efficacy and tolerability of levodopa in Parkinson's disease. Expert Rev Neurother. 2022 06; 22(6):489-498.
Score: 0.020
-
Dystonic motor and phonic tics in Tourette syndrome. J Neurol. 2022 Oct; 269(10):5312-5318.
Score: 0.020
-
The clinical phenomenology and correlations of oculogyric tics. Acta Neurol Belg. 2022 Aug; 122(4):925-930.
Score: 0.020
-
Slowing Parkinson's Disease Progression with Vaccination and Other Immunotherapies. CNS Drugs. 2022 04; 36(4):327-343.
Score: 0.020
-
Sports-Related Dystonia. Tremor Other Hyperkinet Mov (N Y). 2021; 11:54.
Score: 0.020
-
Self-injurious behavior in Tourette syndrome. J Neurol. 2022 May; 269(5):2453-2459.
Score: 0.019
-
Safety and Efficacy of Flexible-Dose Deutetrabenazine in Children and Adolescents With Tourette Syndrome: A Randomized Clinical Trial. JAMA Netw Open. 2021 10 01; 4(10):e2128204.
Score: 0.019
-
Editorial "Parkinsonism across the spectrum of movement disorders and beyond". J Neurol Sci. 2022 Feb 15; 433:120013.
Score: 0.019
-
The etiopathogenetic and pathophysiological spectrum of parkinsonism. J Neurol Sci. 2022 Feb 15; 433:120012.
Score: 0.019
-
Parkinsonism and tremor syndromes. J Neurol Sci. 2022 Feb 15; 433:120018.
Score: 0.019
-
The Clinical Value of Patient Home Videos in Movement Disorders. Tremor Other Hyperkinet Mov (N Y). 2021; 11:37.
Score: 0.019
-
Duration and onset of effect of incobotulinumtoxinA for the treatment of blepharospasm in botulinum toxin-na?ve subjects. Curr Med Res Opin. 2021 10; 37(10):1761-1768.
Score: 0.019
-
Exploring the role of botulinum toxin in critical care. Expert Rev Neurother. 2021 08; 21(8):881-894.
Score: 0.019
-
Beyond tics: movement disorders in patients with Tourette syndrome. J Neural Transm (Vienna). 2021 08; 128(8):1177-1183.
Score: 0.019
-
Phenotypic Features of Isolated Essential Tremor, Essential Tremor Plus, and Essential Tremor-Parkinson's Disease in a Movement Disorders Clinic. Tremor Other Hyperkinet Mov (N Y). 2021 03 29; 11:12.
Score: 0.019
-
Botulinum Neurotoxin Injections in Childhood Opisthotonus. Toxins (Basel). 2021 02 12; 13(2).
Score: 0.019
-
Parkinson's disease after COVID-19. J Neurol Sci. 2021 03 15; 422:117331.
Score: 0.019
-
Botulinum Toxin in Movement Disorders: An Update. Toxins (Basel). 2021 Jan 08; 13(1).
Score: 0.019
-
Parkinson's disease and skin. Parkinsonism Relat Disord. 2021 01; 82:61-76.
Score: 0.018
-
Reply to: "Toward a Personalized Approach to Parkinson's Cell Therapy". Mov Disord. 2020 11; 35(11):2120-2121.
Score: 0.018
-
Current Management of Tics and Tourette Syndrome: Behavioral, Pharmacologic, and Surgical Treatments. Neurotherapeutics. 2020 10; 17(4):1681-1693.
Score: 0.018
-
A validation of a self-administered screening test for Parkinson's disease. J Neurol Sci. 2020 Nov 15; 418:117116.
Score: 0.018
-
Stem Cells: Scientific and Ethical Quandaries of a Personalized Approach to Parkinson's Disease. Mov Disord. 2020 08; 35(8):1312-1314.
Score: 0.018
-
Parkinson's disease: etiopathogenesis and treatment. J Neurol Neurosurg Psychiatry. 2020 08; 91(8):795-808.
Score: 0.018
-
Parkinson disease and the immune system - associations, mechanisms and therapeutics. Nat Rev Neurol. 2020 06; 16(6):303-318.
Score: 0.018
-
Treatment of Tardive Dyskinesia. Neurol Clin. 2020 05; 38(2):379-396.
Score: 0.017
-
Treatment of tics associated with Tourette syndrome. J Neural Transm (Vienna). 2020 05; 127(5):843-850.
Score: 0.017
-
[Essential tremor: genetic update]. Expert Rev Mol Med. 2019 12 10; 21:e8.
Score: 0.017
-
Are the International Parkinson disease and Movement Disorder Society progressive supranuclear palsy (IPMDS-PSP) diagnostic criteria accurate enough to differentiate common PSP phenotypes? Parkinsonism Relat Disord. 2019 12; 69:34-39.
Score: 0.017
-
Immunogenicity Associated with Botulinum Toxin Treatment. Toxins (Basel). 2019 08 26; 11(9).
Score: 0.017
-
Psychogenic (Functional) Movement Disorders. Continuum (Minneap Minn). 2019 Aug; 25(4):1121-1140.
Score: 0.017
-
Juvenile parkinsonism: Differential diagnosis, genetics, and treatment. Parkinsonism Relat Disord. 2019 10; 67:74-89.
Score: 0.017
-
Targeting a-Synuclein in Parkinson's Disease: Progress Towards the Development of Disease-Modifying Therapeutics. Drugs. 2019 Jun; 79(8):797-810.
Score: 0.017
-
Young-onset Parkinson's disease: Its unique features and their impact on quality of life. Parkinsonism Relat Disord. 2019 08; 65:39-48.
Score: 0.017
-
Clinical phenotype in carriers of intermediate alleles in the huntingtin gene. J Neurol Sci. 2019 Jul 15; 402:57-61.
Score: 0.017
-
Real-World Experience With VMAT2 Inhibitors. Clin Neuropharmacol. 2019 Mar/Apr; 42(2):37-41.
Score: 0.016
-
Hand, foot, and spine deformities in parkinsonian disorders. J Neural Transm (Vienna). 2019 03; 126(3):253-264.
Score: 0.016
-
The Wide Spectrum of Functional Movement Disorders. JAMA Neurol. 2019 02 01; 76(2):235-236.
Score: 0.016
-
Botulinum toxin for the treatment of tremor. Parkinsonism Relat Disord. 2019 06; 63:31-41.
Score: 0.016
-
Essential Tremor and Parkinson's Disease: Exploring the Relationship. Tremor Other Hyperkinet Mov (N Y). 2018; 8:589.
Score: 0.016
-
Pathogenesis-targeted therapeutic strategies in Parkinson's disease. Mov Disord. 2019 01; 34(1):41-44.
Score: 0.016
-
Reader response: The nature of postural tremor in Parkinson disease. Neurology. 2018 10 09; 91(15):723.
Score: 0.016
-
Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-a-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol. 2018 10 01; 75(10):1206-1214.
Score: 0.016
-
Huntington disease: A quarter century of progress since the gene discovery. J Neurol Sci. 2019 01 15; 396:52-68.
Score: 0.016
-
Essential Tremor. N Engl J Med. 2018 08 09; 379(6):595.
Score: 0.016
-
Botulinum Toxin for the Treatment of Hand Tremor. Toxins (Basel). 2018 07 19; 10(7).
Score: 0.016
-
Deutetrabenazine for the treatment of Huntington's chorea. Expert Rev Neurother. 2018 08; 18(8):625-631.
Score: 0.016
-
Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors. Drugs. 2018 04; 78(5):525-541.
Score: 0.015
-
Cervical dystonia and substance abuse. J Neurol. 2018 Apr; 265(4):970-975.
Score: 0.015
-
Parkinson's disease tremors and serotonin. Brain. 2018 03 01; 141(3):624-626.
Score: 0.015
-
Tardive syndromes. J Neurol Sci. 2018 06 15; 389:35-42.
Score: 0.015
-
Immunologic treatment of Parkinson's disease. Immunotherapy. 2018 02; 10(2):81-84.
Score: 0.015
-
Onabotulinum toxin-A injections for sleep bruxism: A double-blind, placebo-controlled study. Neurology. 2018 02 13; 90(7):e559-e564.
Score: 0.015
-
Leg stereotypy syndrome: phenomenology and prevalence. J Neurol Neurosurg Psychiatry. 2018 07; 89(7):692-695.
Score: 0.015
-
The Role of TMEM230 Gene in Parkinson's Disease. J Parkinsons Dis. 2018; 8(4):469-477.
Score: 0.015
-
Autoimmune and paraneoplastic movement disorders: An update. J Neurol Sci. 2018 02 15; 385:175-184.
Score: 0.015
-
The genetics of Parkinson disease. Ageing Res Rev. 2018 Mar; 42:72-85.
Score: 0.015
-
Treatment options for chorea. Expert Rev Neurother. 2018 Jan; 18(1):51-63.
Score: 0.015
-
Parkinson disease: Exenatide - a drug for diabetes and Parkinson disease? Nat Rev Neurol. 2017 Nov; 13(11):643-644.
Score: 0.015
-
An update on new and unique uses of botulinum toxin in movement disorders. Toxicon. 2018 Jun 01; 147:84-88.
Score: 0.015
-
Anosmia and Ageusia in Parkinson's Disease. Int Rev Neurobiol. 2017; 133:541-556.
Score: 0.014
-
Functional (psychogenic) stereotypies. J Neurol. 2017 Jul; 264(7):1482-1487.
Score: 0.014
-
Botulinum toxin: State of the art. Mov Disord. 2017 Aug; 32(8):1131-1138.
Score: 0.014
-
Diagnosis and Management of Parkinson's Disease. Semin Neurol. 2017 04; 37(2):118-126.
Score: 0.014
-
Media hype: Patient and scientific perspectives on misleading medical news. Mov Disord. 2017 Sep; 32(9):1319-1323.
Score: 0.014
-
Apraclonidine in the treatment of ptosis. J Neurol Sci. 2017 May 15; 376:129-132.
Score: 0.014
-
Letter re: Huntington disease reduced penetrance alleles occur at high frequency in the general population. Neurology. 2017 01 17; 88(3):334.
Score: 0.014
-
Movement disorders in 2016: Progress in Parkinson disease and other movement disorders. Nat Rev Neurol. 2017 Feb; 13(2):76-78.
Score: 0.014
-
Examiner manoeuvres 'sensory tricks' in functional (psychogenic) movement disorders. J Neurol Neurosurg Psychiatry. 2017 05; 88(5):453-455.
Score: 0.014
-
Distinguishing features of psychogenic (functional) versus organic hemifacial spasm. J Neurol. 2017 Feb; 264(2):359-363.
Score: 0.014
-
Dopamine depleters in the treatment of hyperkinetic movement disorders. Expert Opin Pharmacother. 2016 Dec; 17(18):2461-2470.
Score: 0.014
-
Treatment of blepharospasm with apraclonidine. J Neurol Sci. 2017 Jan 15; 372:57-59.
Score: 0.014
-
Neuropsychological outcomes from constant current deep brain stimulation for Parkinson's disease. Mov Disord. 2017 03; 32(3):433-440.
Score: 0.014
-
Functional (psychogenic) saccadic oscillations and oculogyric crises. Lancet Neurol. 2016 07; 15(8):791.
Score: 0.014
-
Drug-Induced Dyskinesia, Part 2: Treatment of Tardive Dyskinesia. Drugs. 2016 May; 76(7):779-87.
Score: 0.013
-
Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia. Drugs. 2016 May; 76(7):759-77.
Score: 0.013
-
New and emerging medical therapies in Parkinson's disease. Expert Opin Pharmacother. 2016; 17(7):895-909.
Score: 0.013
-
Parkinsonism, movement disorders and genetics in frontotemporal dementia. Nat Rev Neurol. 2016 Mar; 12(3):175-85.
Score: 0.013
-
Botulinum Toxin for the Treatment of Tremor and Tics. Semin Neurol. 2016 Feb; 36(1):54-63.
Score: 0.013
-
Psychogenic Ophthalmologic Movement Disorders. J Neuropsychiatry Clin Neurosci. 2016; 28(3):195-8.
Score: 0.013
-
Movement disorders induced by deep brain stimulation. Parkinsonism Relat Disord. 2016 Apr; 25:1-9.
Score: 0.013
-
Psychogenic (functional) parkinsonism. Handb Clin Neurol. 2016; 139:259-262.
Score: 0.013
-
Clinical and scientific perspectives on movement disorders: Stanley Fahn's contributions. Mov Disord. 2015 Dec; 30(14):1862-9.
Score: 0.013
-
The relationship between essential tremor and Parkinson's disease. Parkinsonism Relat Disord. 2016 Jan; 22 Suppl 1:S162-5.
Score: 0.013
-
Therapeutic Developments for Tics and Myoclonus. Mov Disord. 2015 Sep 15; 30(11):1566-73.
Score: 0.013
-
Leg stereotypy disorder. J Neurol Neurosurg Psychiatry. 2016 Feb; 87(2):220-1.
Score: 0.013
-
Speech and voice disorders in patients with psychogenic movement disorders. J Neurol. 2015 Nov; 262(11):2420-4.
Score: 0.013
-
Dopamine transporter imaging in essential tremor with and without parkinsonian features. J Neural Transm (Vienna). 2015 Nov; 122(11):1515-21.
Score: 0.013
-
Dopa-responsive dystonia--clinical and genetic heterogeneity. Nat Rev Neurol. 2015 Jul; 11(7):414-24.
Score: 0.013
-
Genetics and molecular biology of brain calcification. Ageing Res Rev. 2015 Jul; 22:20-38.
Score: 0.012
-
Restless legs syndrome: clinical presentation diagnosis and treatment. Sleep Med. 2015 Jun; 16(6):678-90.
Score: 0.012
-
The therapeutic potential of cannabinoids for movement disorders. Mov Disord. 2015 Mar; 30(3):313-27.
Score: 0.012
-
Paroxysmal movement disorders. Neurol Clin. 2015 Feb; 33(1):137-52.
Score: 0.012
-
Psychogenic movement disorders. Neurol Clin. 2015 Feb; 33(1):205-24.
Score: 0.012
-
Gait disorders. Neurol Clin. 2015 Feb; 33(1):249-68.
Score: 0.012
-
Movement disorders. Neurol Clin. 2015 Feb; 33(1):xv-xvi.
Score: 0.012
-
Bolivian kindred with combined spinocerebellar ataxia types 2 and 10. Acta Neurol Scand. 2015 Aug; 132(2):139-42.
Score: 0.012
-
Primary results from the cervical dystonia patient registry for observation of onabotulinumtoxina efficacy (CD PROBE). J Neurol Sci. 2015 Feb 15; 349(1-2):84-93.
Score: 0.012
-
Stiff-person syndrome: insights into a complex autoimmune disorder. J Neurol Neurosurg Psychiatry. 2015 Aug; 86(8):840-8.
Score: 0.012
-
Genetic movement disorders in patients of Jewish ancestry. JAMA Neurol. 2014 Dec; 71(12):1567-72.
Score: 0.012
-
Movement disorders in catatonia. J Neurol Neurosurg Psychiatry. 2015 Aug; 86(8):825-32.
Score: 0.012
-
The future of research in Parkinson disease. JAMA Neurol. 2014 Nov; 71(11):1351-2.
Score: 0.012
-
Randomized trial of IV valproate vs metoclopramide vs ketorolac for acute migraine. Neurology. 2014 Oct 07; 83(15):1388-9.
Score: 0.012
-
Effects of long-term treatment with rotigotine transdermal system on dyskinesia in patients with early-stage Parkinson's disease. Parkinsonism Relat Disord. 2014 Dec; 20(12):1345-51.
Score: 0.012
-
"Psychogenic" versus "functional" movement disorders? That is the question. Mov Disord. 2014 Nov; 29(13):1697-8.
Score: 0.012
-
Chorea associated with Huntington's disease: to treat or not to treat? Mov Disord. 2014 Sep 15; 29(11):1414-8.
Score: 0.012
-
Long-term efficacy, safety, and side effect profile of botulinum toxin in dystonia: a 20-year follow-up. Toxicon. 2014 Nov; 90:344-8.
Score: 0.012
-
Genetic convergence of Parkinson's disease and lysosomal storage disorders. Mol Neurobiol. 2015; 51(3):1554-68.
Score: 0.012
-
The role of FUS gene variants in neurodegenerative diseases. Nat Rev Neurol. 2014 Jun; 10(6):337-48.
Score: 0.012
-
Parkinson disease subtypes. JAMA Neurol. 2014 Apr; 71(4):499-504.
Score: 0.012
-
Symptomatic efficacy of rasagiline monotherapy in early Parkinson's disease: post-hoc analyses from the ADAGIO trial. Parkinsonism Relat Disord. 2014 Jun; 20(6):640-3.
Score: 0.012
-
Treatment of dystonia. Neurotherapeutics. 2014 Jan; 11(1):139-52.
Score: 0.011
-
Animal models of Parkinson's disease: a gateway to therapeutics? Neurotherapeutics. 2014 Jan; 11(1):92-110.
Score: 0.011
-
Editorial: Neurotherapeutics of movement disorders. Neurotherapeutics. 2014 Jan; 11(1):3-5.
Score: 0.011
-
The clinical features of psychogenic movement disorders resembling tics. J Neurol Neurosurg Psychiatry. 2014 May; 85(5):573-5.
Score: 0.011
-
Long-term efficacy and safety of fluphenazine in patients with Tourette syndrome. Mov Disord. 2014 Jan; 29(1):126-30.
Score: 0.011
-
Restless legs syndrome and cerebrovascular disease - authors' reply. Lancet Neurol. 2013 Aug; 12(8):734-5.
Score: 0.011
-
Medical treatment of dystonia. Mov Disord. 2013 Jun 15; 28(7):1001-12.
Score: 0.011
-
Flu-like symptoms and associated immunological response following therapy with botulinum toxins. Neurotox Res. 2013 Aug; 24(2):298-306.
Score: 0.011
-
Deep brain stimulation of the subthalamic nucleus for peripherally induced parkinsonism. Neuromodulation. 2014 Jan; 17(1):104-6.
Score: 0.011
-
Zolpidem improves tardive dyskinesia and akathisia. Mov Disord. 2013 Oct; 28(12):1748-9.
Score: 0.011
-
Movement disorders in cerebrovascular disease. Lancet Neurol. 2013 Jun; 12(6):597-608.
Score: 0.011
-
Bilateral globus pallidus internus deep brain stimulation after bilateral pallidotomy in a patient with generalized early-onset primary dystonia. Mov Disord. 2013 Jul; 28(8):1162-3.
Score: 0.011
-
The VPS35 gene and Parkinson's disease. Mov Disord. 2013 May; 28(5):569-75.
Score: 0.011
-
Yips and other movement disorders in golfers. Mov Disord. 2013 May; 28(5):576-81.
Score: 0.011
-
Movement disorders in multiple sclerosis and other demyelinating diseases. J Neurol Sci. 2013 May 15; 328(1-2):1-8.
Score: 0.011
-
Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders. Toxicon. 2013 Jun 01; 67:94-114.
Score: 0.011
-
Long-term efficacy and safety of botulinum toxin injections in dystonia. Toxins (Basel). 2013 Feb 04; 5(2):249-66.
Score: 0.011
-
F-box only protein 7 gene in parkinsonian-pyramidal disease. JAMA Neurol. 2013 Jan; 70(1):20-4.
Score: 0.011
-
Analysis of CYP2D6 genotype and response to tetrabenazine. Mov Disord. 2013 Feb; 28(2):210-5.
Score: 0.011
-
Respiratory disorders associated with dystonia. Mov Disord. 2012 Dec; 27(14):1816-9.
Score: 0.011
-
Spinocerebellar ataxia types 2 and 10: more than a coincidental association? Arch Neurol. 2012 Nov; 69(11):1524-5; Author reply 1525.
Score: 0.011
-
Huntington's disease: how intermediate are intermediate repeat lengths? Mov Disord. 2012 Dec; 27(14):1714-7.
Score: 0.010
-
The role of alpha-synuclein in melanin synthesis in melanoma and dopaminergic neuronal cells. PLoS One. 2012; 7(9):e45183.
Score: 0.010
-
Therapies in Parkinson's disease. Curr Opin Neurol. 2012 Aug; 25(4):433-47.
Score: 0.010
-
Current concepts in Parkinson's disease and other movement disorders. Curr Opin Neurol. 2012 Aug; 25(4):429-32.
Score: 0.010
-
Amplitude fluctuations in essential tremor. Parkinsonism Relat Disord. 2012 Aug; 18(7):859-63.
Score: 0.010
-
Movement disorders in autoimmune diseases. Mov Disord. 2012 Jul; 27(8):935-46.
Score: 0.010
-
The genetics of Tourette syndrome. Nat Rev Neurol. 2012 Mar 13; 8(4):203-13.
Score: 0.010
-
Long-term safety and tolerability of rotigotine transdermal system in patients with early-stage idiopathic Parkinson's disease: a prospective, open-label extension study. Parkinsonism Relat Disord. 2012 Jun; 18(5):488-93.
Score: 0.010
-
Rationale and design of a prospective study: Cervical Dystonia Patient Registry for Observation of OnaBotulinumtoxinA Efficacy (CD PROBE). BMC Neurol. 2011 Nov 04; 11:140.
Score: 0.010
-
Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders. Expert Rev Neurother. 2011 Nov; 11(11):1509-23.
Score: 0.010
-
Convergence spasm in conversion disorders: prevalence in psychogenic and other movement disorders compared with controls. J Neurol Neurosurg Psychiatry. 2012 Feb; 83(2):202-4.
Score: 0.010
-
Pain in Parkinson's disease. Mov Disord. 2012 Apr; 27(4):485-91.
Score: 0.010
-
Diagnosis and treatment of psychogenic parkinsonism. J Neurol Neurosurg Psychiatry. 2011 Dec; 82(12):1300-3.
Score: 0.010
-
The prevalence of symptomatic orthostatic hypotension in patients with Parkinson's disease and atypical parkinsonism. Parkinsonism Relat Disord. 2011 Sep; 17(8):625-8.
Score: 0.010
-
Exploring the correlates of intermediate CAG repeats in Huntington disease. Postgrad Med. 2011 Sep; 123(5):116-21.
Score: 0.010
-
Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm-a randomized trial. Mov Disord. 2011 Jul; 26(8):1521-8.
Score: 0.009
-
Parkinsonism and dystonia associated with adalimumab. Mov Disord. 2011 Jul; 26(8):1556-8.
Score: 0.009
-
Tourette syndrome: evolving concepts. Mov Disord. 2011 May; 26(6):1149-56.
Score: 0.009
-
The many faces of hemifacial spasm: differential diagnosis of unilateral facial spasms. Mov Disord. 2011 Aug 01; 26(9):1582-92.
Score: 0.009
-
The association between Parkinson's disease and melanoma. Int J Cancer. 2011 May 15; 128(10):2251-60.
Score: 0.009
-
Caudate glucose hypometabolism in a subject carrying an unstable allele of intermediate CAG(33) repeat length in the Huntington's disease gene. Mov Disord. 2011 Apr; 26(5):925-7.
Score: 0.009
-
Revisiting the relationship between essential tremor and Parkinson's disease. Mov Disord. 2011 Feb 15; 26(3):391-8.
Score: 0.009
-
Preclinical biomarkers of Parkinson disease. Arch Neurol. 2011 Jan; 68(1):22-30.
Score: 0.009
-
Transcutaneous electrical stimulation (TENS) for psychogenic movement disorders. J Neuropsychiatry Clin Neurosci. 2011; 23(2):141-8.
Score: 0.009
-
An introduction to dyskinesia--the clinical spectrum. Int Rev Neurobiol. 2011; 98:1-29.
Score: 0.009
-
Asian over-representation among patients with hemifacial spasm compared to patients with cranial-cervical dystonia. J Neurol Sci. 2010 Nov 15; 298(1-2):61-3.
Score: 0.009
-
Alcohol in essential tremor and other movement disorders. Mov Disord. 2010 Oct 30; 25(14):2274-84.
Score: 0.009
-
Tourette's syndrome in adults. Mov Disord. 2010 Oct 15; 25(13):2171-5.
Score: 0.009
-
Correlation between Kinesia system assessments and clinical tremor scores in patients with essential tremor. Mov Disord. 2010 Sep 15; 25(12):1938-43.
Score: 0.009
-
Respiratory problems in neurologic movement disorders. Parkinsonism Relat Disord. 2010 Dec; 16(10):628-38.
Score: 0.009
-
Tardive dyskinesia and withdrawal emergent syndrome in children. Expert Rev Neurother. 2010 Jun; 10(6):893-901.
Score: 0.009
-
Reply: Based on the available randomized trial patients should say no to glutathione for Parkinson's disease. Mov Disord. 2010 May 15; 25(7):961-2; author reply 962-3.
Score: 0.009
-
Camptocormia, head drop and other bent spine syndromes: heterogeneous etiology and pathogenesis of Parkinsonian deformities. Mov Disord. 2010 Apr 15; 25(5):527-8.
Score: 0.009
-
Advances in the pharmacological management of Huntington's disease. Drugs. 2010 Mar 26; 70(5):561-71.
Score: 0.009
-
Psychogenic chorea associated with family history of Huntington disease. Mov Disord. 2010 Mar 15; 25(4):503-4.
Score: 0.009
-
Examination of the MASH1 gene in patients with Parkinson's disease. Biochem Biophys Res Commun. 2010 Feb 19; 392(4):548-50.
Score: 0.009
-
Examination of the MSX1 gene in patients with Parkinson's disease. Acta Neurol Scand. 2009 Dec; 120(6):442-4.
Score: 0.009
-
Clinical efficacy and tolerability of Xeomin in the treatment of blepharospasm. Eur J Neurol. 2009 Dec; 16 Suppl 2:14-8.
Score: 0.009
-
Treatment of dysautonomia associated with Parkinson's disease. Parkinsonism Relat Disord. 2009 Dec; 15 Suppl 3:S224-32.
Score: 0.009
-
Genetic analysis of the NEUROG2 gene in patients with Parkinson's disease. Neurosci Lett. 2010 Jan 14; 468(3):195-7.
Score: 0.009
-
Motor-phonic tic mimicking essential palatal myoclonus. Mov Disord. 2009 Oct 15; 24(13):2030-2.
Score: 0.009
-
Relationship between neuropsychological outcome and DBS surgical trajectory and electrode location. J Neurol Sci. 2009 Dec 15; 287(1-2):159-71.
Score: 0.008
-
Education research: patient telephone calls in a movement disorders center: lessons in physician-trainee education. Neurology. 2009 Sep 08; 73(10):e50-2.
Score: 0.008
-
Treatment of hyperkinetic movement disorders. Lancet Neurol. 2009 Sep; 8(9):844-56.
Score: 0.008
-
Impact of STN-DBS on life and health satisfaction in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry. 2010 Mar; 81(3):315-9.
Score: 0.008
-
A randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome. J Neurol Neurosurg Psychiatry. 2010 Jan; 81(1):70-3.
Score: 0.008
-
Movement disorders. Preface. Neurol Clin. 2009 Aug; 27(3):ix-x.
Score: 0.008
-
Peripherally induced movement disorders. Neurol Clin. 2009 Aug; 27(3):821-32, vii.
Score: 0.008
-
Efficacy and tolerability of pregabalin in essential tremor: a randomized, double-blind, placebo-controlled, crossover trial. J Neurol Sci. 2009 Oct 15; 285(1-2):195-7.
Score: 0.008
-
Spinocerebellar ataxia 8: variable phenotype and unique pathogenesis. Parkinsonism Relat Disord. 2009 Nov; 15(9):621-6.
Score: 0.008
-
Motor overflow and mirror dystonia. Parkinsonism Relat Disord. 2009 Dec; 15(10):758-61.
Score: 0.008
-
Transcription factor PITX3 gene in Parkinson's disease. Neurobiol Aging. 2011 Apr; 32(4):750-3.
Score: 0.008
-
Atomoxetine for freezing of gait in Parkinson disease. J Neurol Sci. 2009 Sep 15; 284(1-2):177-8.
Score: 0.008
-
Hemidystonia-hemiatrophy syndrome. Mov Disord. 2009 Mar 15; 24(4):583-9.
Score: 0.008
-
Acquired hepatocerebral degeneration. J Neurol. 2009 Mar; 256(3):320-32.
Score: 0.008
-
Relationship between various clinical outcome assessments in patients with blepharospasm. Mov Disord. 2009 Feb 15; 24(3):407-13.
Score: 0.008
-
Unique properties of botulinum toxins. Toxicon. 2009 Oct; 54(5):675.
Score: 0.008
-
Epidemiology and management of essential tremor in children. Paediatr Drugs. 2009; 11(5):293-307.
Score: 0.008
-
Applause sign in Parkinsonian disorders and Huntington's disease. Mov Disord. 2008 Dec 15; 23(16):2307-11.
Score: 0.008
-
Disease-oriented approach to botulinum toxin use. Toxicon. 2009 Oct; 54(5):614-23.
Score: 0.008
-
Etiopathogenesis of Parkinson disease: a new beginning? Neuroscientist. 2009 Feb; 15(1):28-35.
Score: 0.008
-
Movement disorders in musicians. Mov Disord. 2008 Oct 30; 23(14):1957-65.
Score: 0.008
-
Genetic study of an American family with DYT3 dystonia (lubag). Neurosci Lett. 2008 Dec 26; 448(2):180-3.
Score: 0.008
-
Psychogenic movement disorders in children. Mov Disord. 2008 Oct 15; 23(13):1875-81.
Score: 0.008
-
Decreased NURR1 gene expression in patients with Parkinson's disease. J Neurol Sci. 2008 Oct 15; 273(1-2):29-33.
Score: 0.008
-
Shoulder pain: a presenting symptom of Parkinson disease. J Clin Rheumatol. 2008 Aug; 14(4):253-4.
Score: 0.008
-
A study of chorea after tetrabenazine withdrawal in patients with Huntington disease. Clin Neuropharmacol. 2008 May-Jun; 31(3):127-33.
Score: 0.008
-
Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008 Apr; 79(4):368-76.
Score: 0.008
-
Symptomatic treatment of Huntington disease. Neurotherapeutics. 2008 Apr; 5(2):181-97.
Score: 0.008
-
Bilateral pedunculopontine nuclei strokes presenting as freezing of gait. Mov Disord. 2008 Mar 15; 23(4):616-9.
Score: 0.008
-
Impulse control disorders and pathological gambling in patients with Parkinson disease. Neurologist. 2008 Mar; 14(2):89-99.
Score: 0.008
-
Are adenosine antagonists, such as istradefylline, caffeine, and chocolate, useful in the treatment of Parkinson's disease? Ann Neurol. 2008 Mar; 63(3):267-9.
Score: 0.008
-
Metoclopramide, an increasingly recognized cause of tardive dyskinesia. J Clin Pharmacol. 2008 Mar; 48(3):379-84.
Score: 0.008
-
The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease. Brain. 2008 Aug; 131(Pt 8):1969-78.
Score: 0.008
-
Mutation analysis of the parkin and PINK1 genes in American Caucasian early-onset Parkinson disease families. Neurosci Lett. 2008 Jan 03; 430(1):18-22.
Score: 0.008
-
Parkinson's disease and movement disorders: moving forward. Lancet Neurol. 2008 Jan; 7(1):9-11.
Score: 0.008
-
Clinical aspects of progressive supranuclear palsy. Handb Clin Neurol. 2008; 89:461-73.
Score: 0.008
-
Tardive gait. Clin Neurol Neurosurg. 2008 Feb; 110(2):198-201.
Score: 0.007
-
Mozart's movements and behaviour: a case of Tourette's syndrome? J Neurol Neurosurg Psychiatry. 2007 Nov; 78(11):1171-5.
Score: 0.007
-
Hyperhidrosis due to deep brain stimulation in a patient with essential tremor. Case report. J Neurosurg. 2007 Nov; 107(5):1036-8.
Score: 0.007
-
Cognitive declines following bilateral subthalamic nucleus deep brain stimulation for the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry. 2008 Jul; 79(7):789-95.
Score: 0.007
-
Hemiparkinsonism-hemiatrophy syndrome. Neurology. 2007 Oct 16; 69(16):1585-94.
Score: 0.007
-
Focal hand dystonia, mirror dystonia and motor overflow. J Neurol Sci. 2008 Mar 15; 266(1-2):31-3.
Score: 0.007
-
Malignant Tourette syndrome. Mov Disord. 2007 Sep 15; 22(12):1743-50.
Score: 0.007
-
Overnight switch from oral dopaminergic agonists to transdermal rotigotine patch in subjects with Parkinson disease. Clin Neuropharmacol. 2007 Sep-Oct; 30(5):256-65.
Score: 0.007
-
Are Parkinson disease patients protected from some but not all cancers? Neurology. 2007 Oct 09; 69(15):1542-50.
Score: 0.007
-
The other Babinski sign in hemifacial spasm. Neurology. 2007 Jul 24; 69(4):402-4.
Score: 0.007
-
Alexia without agraphia in Creutzfeldt-Jakob disease. J Neurol Sci. 2007 Dec 15; 263(1-2):208-10.
Score: 0.007
-
Hereditary chin tremor in Parkinson's disease. Clin Neurol Neurosurg. 2007 Nov; 109(9):784-5.
Score: 0.007
-
Candidate locus for chorea and tic disorders at 15q? Pediatr Neurol. 2007 Jul; 37(1):70-3.
Score: 0.007
-
Distinguishing psychogenic and essential tremor. J Neurol Sci. 2007 Dec 15; 263(1-2):94-9.
Score: 0.007
-
Botulinum toxin in the treatment of blepharospasm and hemifacial spasm. J Neural Transm (Vienna). 2008; 115(4):585-91.
Score: 0.007
-
The effects of subthalamic nucleus deep brain stimulation on parkinsonian tremor. J Neurol Sci. 2007 Sep 15; 260(1-2):199-203.
Score: 0.007
-
Botulinum toxin in the treatment of tremors, dystonias, sialorrhea and other symptoms associated with Parkinson's disease. Expert Rev Neurother. 2007 Jun; 7(6):637-47.
Score: 0.007
-
Rotigotine transdermal patch in the treatment of Parkinson's disease and restless legs syndrome. Expert Opin Pharmacother. 2007 Jun; 8(9):1329-35.
Score: 0.007
-
Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease. Arch Neurol. 2007 May; 64(5):676-82.
Score: 0.007
-
Genetic analysis of LRRK2 P755L variant in Caucasian patients with Parkinson's disease. Neurosci Lett. 2007 May 29; 419(2):104-7.
Score: 0.007
-
Prevalence of cervical dystonia and spasmodic torticollis in the United States general population. Parkinsonism Relat Disord. 2007 Oct; 13(7):411-6.
Score: 0.007
-
Short-term and long-term safety of deep brain stimulation in the treatment of movement disorders. J Neurosurg. 2007 Apr; 106(4):621-5.
Score: 0.007
-
Genetics of essential tremor. Brain. 2007 Jun; 130(Pt 6):1456-64.
Score: 0.007
-
A family with Parkinson disease, essential tremor, bell palsy, and parkin mutations. Arch Neurol. 2007 Mar; 64(3):421-4.
Score: 0.007
-
Adult onset tics after peripheral injury. Parkinsonism Relat Disord. 2008; 14(1):75-6.
Score: 0.007
-
Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord. 2007 Jan 15; 22(2):193-7.
Score: 0.007
-
GPi deep brain stimulation for Tourette syndrome improves tics and psychiatric comorbidities. Neurology. 2007 Jan 09; 68(2):159-60.
Score: 0.007
-
Short-term effects of tetrabenazine on chorea associated with Huntington's disease. Mov Disord. 2007 Jan; 22(1):10-3.
Score: 0.007
-
Autopsy-proven Huntington's disease with 29 trinucleotide repeats. Mov Disord. 2007 Jan; 22(1):127-30.
Score: 0.007
-
Medical management of levodopa-associated motor complications in patients with Parkinson's disease. CNS Drugs. 2007; 21(8):677-92.
Score: 0.007
-
Treatment of dystonia. Parkinsonism Relat Disord. 2007; 13 Suppl 3:S362-8.
Score: 0.007
-
Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. Neurology. 2006 Dec 26; 67(12):2233-5.
Score: 0.007
-
Comparing knowledge and attitudes towards genetic testing in Parkinson's disease in an American and Asian population. J Neurol Sci. 2007 Jan 31; 252(2):113-20.
Score: 0.007
-
Examination of the SLITRK1 gene in Caucasian patients with Tourette syndrome. Acta Neurol Scand. 2006 Dec; 114(6):400-2.
Score: 0.007
-
Genetic analysis of LRRK2 mutations in patients with Parkinson disease. J Neurol Sci. 2006 Dec 21; 251(1-2):102-6.
Score: 0.007
-
Runner's dystonia. J Neurol Sci. 2006 Dec 21; 251(1-2):73-6.
Score: 0.007
-
Joint and skeletal deformities in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Mov Disord. 2006 Nov; 21(11):1856-63.
Score: 0.007
-
Treatment of dystonia. Lancet Neurol. 2006 Oct; 5(10):864-72.
Score: 0.007
-
Botulinum toxin injection for congenital muscular torticollis presenting in children and adults. Neurology. 2006 Sep 26; 67(6):1083-5.
Score: 0.007
-
Botulinum toxin treatment of facial myoclonus in suspected Rasmussen encephalitis. Mov Disord. 2006 Sep; 21(9):1500-2.
Score: 0.007
-
Is history of depression a contraindication to treatment with tetrabenazine? Clin Neuropharmacol. 2006 Sep-Oct; 29(5):259-64.
Score: 0.007
-
Genetic testing in Parkinson disease: promises and pitfalls. Arch Neurol. 2006 Sep; 63(9):1232-7.
Score: 0.007
-
The LRRK2 I2012T, G2019S and I2020T mutations are not common in patients with essential tremor. Neurosci Lett. 2006 Oct 23; 407(2):97-100.
Score: 0.007
-
Exploring the relationship between essential tremor and Parkinson's disease. Parkinsonism Relat Disord. 2007 Mar; 13(2):67-76.
Score: 0.007
-
Subthalamic deep brain stimulation in patients with a previous pallidotomy. Mov Disord. 2006 Aug; 21(8):1252-4.
Score: 0.007
-
Effect of vagal nerve stimulation in a case of Tourette's syndrome and complex partial epilepsy. Mov Disord. 2006 Aug; 21(8):1273-5.
Score: 0.007
-
Treatment of advanced Parkinson's disease. Expert Rev Neurother. 2006 Aug; 6(8):1181-97.
Score: 0.007
-
Psychogenic tremor: long-term outcome. CNS Spectr. 2006 Jul; 11(7):501-8.
Score: 0.007
-
An update on the treatment of Parkinson's disease. Mt Sinai J Med. 2006 Jul; 73(4):682-9.
Score: 0.007
-
A functional variant of the dopamine D3 receptor is associated with risk and age-at-onset of essential tremor. Proc Natl Acad Sci U S A. 2006 Jul 11; 103(28):10753-8.
Score: 0.007
-
Long-term prognosis of patients with psychogenic movement disorders. Parkinsonism Relat Disord. 2006 Sep; 12(6):382-7.
Score: 0.007
-
Botulinum toxin in dermatology - beyond wrinkles and sweat. J Cosmet Dermatol. 2006 Jun; 5(2):169.
Score: 0.007
-
Globus pallidus deep brain stimulation in dystonia. Mov Disord. 2006 May; 21(5):692-5.
Score: 0.007
-
Gene dosage analysis of alpha-synuclein (SNCA) in patients with Parkinson's disease. Mov Disord. 2006 May; 21(5):728-9.
Score: 0.007
-
Long-term evaluation of deep brain stimulation of the thalamus. J Neurosurg. 2006 Apr; 104(4):506-12.
Score: 0.007
-
Botulinum toxin therapy for cervical dystonia. Neurotox Res. 2006 Apr; 9(2-3):145-8.
Score: 0.007
-
Genetic analysis of the GABRA1 gene in patients with essential tremor. Neurosci Lett. 2006 Jun 19; 401(1-2):16-9.
Score: 0.007
-
Drug Insight: from disturbed motility to disordered movement--a review of the clinical benefits and medicolegal risks of metoclopramide. Nat Clin Pract Gastroenterol Hepatol. 2006 Mar; 3(3):138-48.
Score: 0.007
-
Heterogeneous phenotype in a family with compound heterozygous parkin gene mutations. Arch Neurol. 2006 Feb; 63(2):273-7.
Score: 0.007
-
Tetrabenazine in the treatment of hyperkinetic movement disorders. Expert Rev Neurother. 2006 Jan; 6(1):7-17.
Score: 0.007
-
Tourette's syndrome and the law. J Neuropsychiatry Clin Neurosci. 2006; 18(1):86-95.
Score: 0.007
-
Tics associated with other disorders. Adv Neurol. 2006; 99:61-8.
Score: 0.007
-
Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial. J Neurol Neurosurg Psychiatry. 2005 Dec; 76(12):1636-9.
Score: 0.007
-
The role of Nurr1 in the development of dopaminergic neurons and Parkinson's disease. Prog Neurobiol. 2005 Sep-Oct; 77(1-2):128-38.
Score: 0.006
-
Dystonia and other deformities in Parkinson's disease. J Neurol Sci. 2005 Dec 15; 239(1):1-3.
Score: 0.006
-
Autonomic function after botulinum toxin type A or B: a double-blind, randomized trial. Neurology. 2005 Sep 13; 65(5):765-7.
Score: 0.006
-
Palatal myoclonus: an unusual presentation. Mov Disord. 2005 Sep; 20(9):1200-3.
Score: 0.006
-
The effect of deep brain stimulation on quality of life in movement disorders. J Neurol Neurosurg Psychiatry. 2005 Sep; 76(9):1188-93.
Score: 0.006
-
Extended study of A265G variant of HS1BP3 in essential tremor and Parkinson disease. Neurology. 2005 Aug 23; 65(4):651-2.
Score: 0.006
-
Camptocormia: pathogenesis, classification, and response to therapy. Neurology. 2005 Aug 09; 65(3):355-9.
Score: 0.006
-
Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson Disease. Arch Neurol. 2005 Aug; 62(8):1290-5.
Score: 0.006
-
Striatal deformities of the hand and foot in Parkinson's disease. Lancet Neurol. 2005 Jul; 4(7):423-31.
Score: 0.006
-
Searching for a relationship between manganese and welding and Parkinson's disease. Neurology. 2005 Jun 28; 64(12):2021-8.
Score: 0.006
-
Real-World Experiences with VMAT2 Inhibitors in Pediatric Hyperkinetic Movement Disorders. Tremor Other Hyperkinet Mov (N Y). 2025; 15:26.
Score: 0.006
-
G309D and W437OPA PINK1 mutations in Caucasian Parkinson's disease patients. Acta Neurol Scand. 2005 Jun; 111(6):351-2.
Score: 0.006
-
Genetic and clinical identification of Parkinson's disease patients with LRRK2 G2019S mutation. Ann Neurol. 2005 Jun; 57(6):933-4.
Score: 0.006
-
Glucagon-like peptide-1 receptor agonists in neurodegenerative diseases: Promises and challenges. Pharmacol Res. 2025 Jun; 216:107770.
Score: 0.006
-
Definition and Classification of Dystonia. Mov Disord. 2025 Jul; 40(7):1248-1259.
Score: 0.006
-
Long-term botulinum toxin efficacy, safety, and immunogenicity. Mov Disord. 2005 May; 20(5):592-7.
Score: 0.006
-
Emerging drugs in Tourette syndrome. Expert Opin Emerg Drugs. 2005 May; 10(2):365-80.
Score: 0.006
-
Secondary tics and tourettism. Braz J Psychiatry. 2005 Mar; 27(1):11-7.
Score: 0.006
-
Genetic analysis of parkin co-regulated gene (PACRG) in patients with early-onset parkinsonism. Neurosci Lett. 2005 Jul 15; 382(3):297-9.
Score: 0.006
-
Genetic mouse models of essential tremor: are they essential? J Clin Invest. 2005 Mar; 115(3):584-6.
Score: 0.006
-
Progression of Parkinson disease: are we making progress in charting the course? Arch Neurol. 2005 Mar; 62(3):351-2.
Score: 0.006
-
Clinical application of botulinum toxin type B in movement disorders and autonomic symptoms. Chin Med Sci J. 2005 Mar; 20(1):44-7.
Score: 0.006
-
Metoclopramide-induced tardive dyskinesia in an infant. Mov Disord. 2005 Jan; 20(1):86-9.
Score: 0.006
-
Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations. Mov Disord. 2005; 20 Suppl 11:S11-6.
Score: 0.006
-
Neuroprotective therapy in Parkinson's disease and motor complications: a search for a pathogenesis-targeted, disease-modifying strategy. Mov Disord. 2005; 20 Suppl 11:S3-10.
Score: 0.006
-
Factor analysis and clustering of motor and psychiatric dimensions in idiopathic blepharospasm. Parkinsonism Relat Disord. 2025 Feb; 131:107241.
Score: 0.006
-
Essential tremor among children. Pediatrics. 2004 Nov; 114(5):1203-5.
Score: 0.006
-
An open-label pilot study of levetiracetam for essential tremor. Clin Neuropharmacol. 2004 Nov-Dec; 27(6):274-7.
Score: 0.006
-
Essential tremor course and disability: a clinicopathologic study of 20 cases. Neurology. 2004 Oct 26; 63(8):1541-2; author reply 1541-2.
Score: 0.006
-
Premutation alleles associated with Parkinson disease and essential tremor. JAMA. 2004 Oct 13; 292(14):1685-6.
Score: 0.006
-
Glabellar and palmomental reflexes in Parkinsonian disorders. Neurology. 2004 Sep 28; 63(6):1096-8.
Score: 0.006
-
Evidence-based review of patient-reported outcomes with botulinum toxin type A. Clin Neuropharmacol. 2004 Sep-Oct; 27(5):234-44.
Score: 0.006
-
Neurodegenerative disease and iron storage in the brain. Curr Opin Neurol. 2004 Aug; 17(4):437-42.
Score: 0.006
-
Botulinum toxin in clinical practice. J Neurol Neurosurg Psychiatry. 2004 Jul; 75(7):951-7.
Score: 0.006
-
Safety of botulinum toxin type A: a systematic review and meta-analysis. Curr Med Res Opin. 2004 Jul; 20(7):981-90.
Score: 0.006
-
Minocycline in Huntington's disease: a pilot study. Mov Disord. 2004 Jun; 19(6):692-5.
Score: 0.006
-
Atypical parkinsonism and motor neuron syndrome in a Biosphere 2 participant: a possible complication of chronic hypoxia and carbon monoxide toxicity? Mov Disord. 2004 Apr; 19(4):465-9.
Score: 0.006
-
Treatment of cervical dystonia with botulinum toxin. Mov Disord. 2004 Mar; 19 Suppl 8:S109-15.
Score: 0.006
-
Current opinions and practices in post-stroke movement disorders: Survey of movement disorders society members. J Neurol Sci. 2024 03 15; 458:122925.
Score: 0.006
-
Efficacy and Safety of DaxibotulinumtoxinA for Injection in Cervical Dystonia: ASPEN-1 Phase 3 Randomized Controlled Trial. Neurology. 2024 02 27; 102(4):e208091.
Score: 0.006
-
Slowing Parkinson's disease progression: recent dopamine agonist trials. Neurology. 2004 Jan 27; 62(2):343; author reply 343-4.
Score: 0.006
-
CADASIL: A NOTCH3-associated cerebral small vessel disease. J Adv Res. 2024 Dec; 66:223-235.
Score: 0.006
-
Basal ganglia neuronal discharge in primary and secondary dystonia. Adv Neurol. 2004; 94:29-36.
Score: 0.006
-
Dystonia: medical therapy and botulinum toxin. Adv Neurol. 2004; 94:275-86.
Score: 0.006
-
Clinical heterogeneity of neurodegeneration with brain iron accumulation (Hallervorden-Spatz syndrome) and pantothenate kinase-associated neurodegeneration. Mov Disord. 2004 Jan; 19(1):36-42.
Score: 0.006
-
Psychogenic movement disorders: diagnosis and management. CNS Drugs. 2004; 18(7):437-52.
Score: 0.006
-
Premonitory sensory phenomenon in Tourette's syndrome. Mov Disord. 2003 Dec; 18(12):1530-3.
Score: 0.006
-
Dopamine agonists in Parkinson's disease. Expert Opin Investig Drugs. 2003 Nov; 12(11):1803-20.
Score: 0.006
-
Migraine headache in patients with Tourette syndrome. Arch Neurol. 2003 Nov; 60(11):1595-8.
Score: 0.006
-
Hearing impairment in essential tremor. Neurology. 2003 Oct 28; 61(8):1093-7.
Score: 0.006
-
Longitudinal predictors of health-related quality of life in isolated dystonia. J Neurol. 2024 Feb; 271(2):852-863.
Score: 0.006
-
Establishing an online resource to facilitate global collaboration and inclusion of underrepresented populations: Experience from the MJFF Global Genetic Parkinson's Disease Project. PLoS One. 2023; 18(10):e0292180.
Score: 0.006
-
Retinal Thickness in Essential Tremor and Early Parkinson Disease: Exploring Diagnostic Insights. J Neuroophthalmol. 2024 Mar 01; 44(1):35-40.
Score: 0.006
-
Neuroprotection in Parkinson disease. Arch Intern Med. 2003 Jul 28; 163(14):1650-4.
Score: 0.006
-
MDMA and Parkinsonism. N Engl J Med. 2003 Jul 03; 349(1):96-7.
Score: 0.005
-
Basal ganglia neuronal discharge in primary and secondary dystonia in patients undergoing pallidotomy. Neurosurgery. 2003 Jun; 52(6):1358-70; discussion 1370-3.
Score: 0.005
-
The role of the PLA2G6 gene in neurodegenerative diseases. Ageing Res Rev. 2023 08; 89:101957.
Score: 0.005
-
Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology. 2003 Apr 08; 60(7):1186-8.
Score: 0.005
-
Isolated Cervical Dystonia: Diagnosis and Classification. Mov Disord. 2023 08; 38(8):1367-1378.
Score: 0.005
-
COVID19-associated new-onset movement disorders: a follow-up study. J Neurol. 2023 May; 270(5):2409-2415.
Score: 0.005
-
Paroxysmal kinesigenic dyskinesias. Semin Pediatr Neurol. 2003 Mar; 10(1):68-79.
Score: 0.005
-
Soleus H-reflex measures in patients with focal and generalized dystonia. Clin Neurophysiol. 2003 Feb; 114(2):288-94.
Score: 0.005
-
Embracing Monogenic Parkinson's Disease: The MJFF Global Genetic PD Cohort. Mov Disord. 2023 02; 38(2):286-303.
Score: 0.005
-
Movement disorders in Friedreich's ataxia. J Neurol Sci. 2003 Jan 15; 206(1):59-64.
Score: 0.005
-
Minocycline and other tetracycline derivatives: a neuroprotective strategy in Parkinson's disease and Huntington's disease. Clin Neuropharmacol. 2003 Jan-Feb; 26(1):18-23.
Score: 0.005
-
Tetrabenazine treatment for Huntington's disease-associated chorea. Clin Neuropharmacol. 2002 Nov-Dec; 25(6):300-2.
Score: 0.005
-
Motor and psychiatric features in idiopathic blepharospasm: A data-driven cluster analysis. Parkinsonism Relat Disord. 2022 11; 104:94-98.
Score: 0.005
-
De novo variants in FRMD5 are associated with developmental delay, intellectual disability, ataxia, and abnormalities of eye movement. Am J Hum Genet. 2022 10 06; 109(10):1932-1943.
Score: 0.005
-
Whole genome sequencing identifies candidate genes for familial essential tremor and reveals biological pathways implicated in essential tremor aetiology. EBioMedicine. 2022 Nov; 85:104290.
Score: 0.005
-
Olanzapine treatment for dopaminergic-induced hallucinations. Mov Disord. 2002 Sep; 17(5):1031-5.
Score: 0.005
-
Association of clinical outcomes and connectivity in awake versus asleep deep brain stimulation for Parkinson disease. J Neurosurg. 2023 04 01; 138(4):1016-1027.
Score: 0.005
-
Treatment options for Parkinson's disease. Curr Opin Neurol. 2002 Aug; 15(4):467-76.
Score: 0.005
-
Essential tremor: a heterogenous disorder. Mov Disord. 2002 Jul; 17(4):638-44.
Score: 0.005
-
Secondary paroxysmal dyskinesias. Mov Disord. 2002 Jul; 17(4):726-34.
Score: 0.005
-
Tourettism and dystonia after subcortical stroke. Mov Disord. 2002 Jul; 17(4):821-5.
Score: 0.005
-
H-reflex recovery curves differentiate essential tremor, Parkinson's disease, and the combination of essential tremor and Parkinson's disease. J Clin Neurophysiol. 2002 Jun; 19(3):245-51.
Score: 0.005
-
The Conundrum of Dystonia in Essential Tremor Patients: How does One Classify these Cases? Tremor Other Hyperkinet Mov (N Y). 2022; 12:15.
Score: 0.005
-
Head injury and posttraumatic movement disorders. Neurosurgery. 2002 May; 50(5):927-39; discussion 939-40.
Score: 0.005
-
Hold that pose: capturing cervical dystonia's head deviation severity from video. Ann Clin Transl Neurol. 2022 05; 9(5):684-694.
Score: 0.005
-
Exploring the relationship between Parkinson disease and restless legs syndrome. Arch Neurol. 2002 Mar; 59(3):421-4.
Score: 0.005
-
A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's disease. Parkinsonism Relat Disord. 2002 Mar; 8(4):271-6.
Score: 0.005
-
Levodopa strengths and weaknesses. Neurology. 2002 Feb 26; 58(4 Suppl 1):S19-32.
Score: 0.005
-
Emerging views of dopamine in modulating sleep/wake state from an unlikely source: PD. Neurology. 2002 Feb 12; 58(3):341-6.
Score: 0.005
-
Association of Essential Tremor With Novel Risk Loci: A Genome-Wide Association Study and Meta-analysis. JAMA Neurol. 2022 02 01; 79(2):185-193.
Score: 0.005
-
Head tremor in cervical dystonia: Quantifying severity with computer vision. J Neurol Sci. 2022 Mar 15; 434:120154.
Score: 0.005
-
Neurodegenerative diseases associated with non-coding CGG tandem repeat expansions. Nat Rev Neurol. 2022 03; 18(3):145-157.
Score: 0.005
-
Dystonia in spinocerebellar ataxia type 6. Mov Disord. 2002 Jan; 17(1):150-3.
Score: 0.005
-
Methods of H-reflex evaluation in the early stages of Parkinson's disease. J Clin Neurophysiol. 2002 Jan; 19(1):67-72.
Score: 0.005
-
Classification of paroxysmal dyskinesias and ataxias. Adv Neurol. 2002; 89:387-400.
Score: 0.005
-
Secondary causes of paroxysmal dyskinesia. Adv Neurol. 2002; 89:401-20.
Score: 0.005
-
Surgery for Parkinson disease and other movement disorders: benefits and limitations of ablation, stimulation, restoration, and radiation. Arch Neurol. 2001 Dec; 58(12):1970-2.
Score: 0.005
-
Botulinum toxin for the treatment of cervical dystonia. Expert Opin Pharmacother. 2001 Dec; 2(12):1985-94.
Score: 0.005
-
Essential tremor. Nat Rev Dis Primers. 2021 11 11; 7(1):83.
Score: 0.005
-
Needle EMG guidance for injection of botulinum toxin. Needle EMG guidance is rarely required. Muscle Nerve. 2001 Nov; 24(11):1568-70.
Score: 0.005
-
Parkinson's disease. A half century of progress. Neurology. 2001 Nov; 57(10 Suppl 3):S1-3.
Score: 0.005
-
Daytime sleepiness and other sleep disorders in Parkinson's disease. Neurology. 2001 Oct 23; 57(8):1392-6.
Score: 0.005
-
Tourette's syndrome. N Engl J Med. 2001 Oct 18; 345(16):1184-92.
Score: 0.005
-
Efficacy and Safety of Fixed-Dose Deutetrabenazine in Children and Adolescents for Tics Associated With Tourette Syndrome: A Randomized Clinical Trial. JAMA Netw Open. 2021 10 01; 4(10):e2129397.
Score: 0.005
-
Dystonia and parkinsonism. Parkinsonism Relat Disord. 2001 Oct; 8(2):109-21.
Score: 0.005
-
Functional decline in Parkinson disease. Arch Neurol. 2001 Oct; 58(10):1611-5.
Score: 0.005
-
Diagnostic criteria for blepharospasm: A multicenter international study. Parkinsonism Relat Disord. 2021 10; 91:109-114.
Score: 0.005
-
Choosing dopamine agonists in Parkinson's disease. Clin Neuropharmacol. 2001 Sep-Oct; 24(5):247-53.
Score: 0.005
-
Predictive modeling of spread in adult-onset isolated dystonia: Key properties and effect of tremor inclusion. Eur J Neurol. 2021 12; 28(12):3999-4009.
Score: 0.005
-
A Multi-center Genome-wide Association Study of Cervical Dystonia. Mov Disord. 2021 12; 36(12):2795-2801.
Score: 0.005
-
Focal dystonia: the role of botulinum toxin. Curr Neurol Neurosci Rep. 2001 Jul; 1(4):337-45.
Score: 0.005
-
Long-term efficacy and safety of botulinum toxin treatment for cervical dystonia: a critical reappraisal. Expert Opin Drug Saf. 2021 Jun; 20(6):695-705.
Score: 0.005
-
Does Raising the Arms Modify Head Tremor Severity in Cervical Dystonia? Tremor Other Hyperkinet Mov (N Y). 2021 06 23; 11:21.
Score: 0.005
-
Clinical-Instrumental patterns of neurodegeneration in Essential Tremor: A data-driven approach. Parkinsonism Relat Disord. 2021 06; 87:124-129.
Score: 0.005
-
Worldwide barriers to genetic testing for movement disorders. Eur J Neurol. 2021 06; 28(6):1901-1909.
Score: 0.005
-
Concepts and methods in chronic thalamic stimulation for treatment of tremor: technique and application. Neurosurgery. 2001 Mar; 48(3):535-41; discussion 541-3.
Score: 0.005
-
Dystonia in corticobasal degeneration. Mov Disord. 2001 Mar; 16(2):252-7.
Score: 0.005
-
Parkinson's disease therapy: treatment of early and late disease. Chin Med J (Engl). 2001 Mar; 114(3):227-34.
Score: 0.005
-
Quantitative mobility measures complement the MDS-UPDRS for characterization of Parkinson's disease heterogeneity. Parkinsonism Relat Disord. 2021 03; 84:105-111.
Score: 0.005
-
Synaptic processes and immune-related pathways implicated in Tourette syndrome. Transl Psychiatry. 2021 01 18; 11(1):56.
Score: 0.005
-
Head tremor and pain in cervical dystonia. J Neurol. 2021 May; 268(5):1945-1950.
Score: 0.005
-
Re-emergence of childhood stuttering in Parkinson's disease: a hypothesis. Mov Disord. 2001 Jan; 16(1):114-8.
Score: 0.005
-
Can peripheral trauma induce dystonia and other movement disorders? Yes! Mov Disord. 2001 Jan; 16(1):7-12.
Score: 0.005
-
Switching from pergolide to pramipexole in patients with Parkinson's disease. J Neural Transm (Vienna). 2001; 108(1):63-70.
Score: 0.005
-
Effects of pallidotomy on gait and balance. Adv Neurol. 2001; 87:271-81.
Score: 0.005
-
Are dopamine receptor agonists neuroprotective in Parkinson's disease? Drugs Aging. 2001; 18(6):389-96.
Score: 0.005
-
Psychogenic hemifacial spasm. J Neuropsychiatry Clin Neurosci. 2001; 13(3):380-4.
Score: 0.005
-
Differential diagnosis and etiology of tics. Adv Neurol. 2001; 85:15-29.
Score: 0.005
-
It's tricky: Rating alleviating maneuvers in cervical dystonia. J Neurol Sci. 2020 Dec 15; 419:117205.
Score: 0.005
-
Dystonia and Tremor: A Cross-Sectional Study of the Dystonia Coalition Cohort. Neurology. 2021 01 26; 96(4):e563-e574.
Score: 0.005
-
Computerized posturography analysis of progressive supranuclear palsy: a case-control comparison with Parkinson's disease and healthy controls. Arch Neurol. 2000 Oct; 57(10):1464-9.
Score: 0.005
-
Parkinson's disease therapy: tailoring choices for early and late disease, young and old patients. Clin Neuropharmacol. 2000 Sep-Oct; 23(5):252-61.
Score: 0.005
-
Clinical and Demographic Characteristics of Upper Limb Dystonia. Mov Disord. 2020 11; 35(11):2086-2090.
Score: 0.005
-
Botulinum toxin in the treatment of tics. Arch Neurol. 2000 Aug; 57(8):1190-3.
Score: 0.004
-
Understanding the relationship between freezing of gait and other progressive supranuclear palsy features. Parkinsonism Relat Disord. 2020 09; 78:56-60.
Score: 0.004
-
Gabapentin for essential tremor: a multiple-dose, double-blind, placebo-controlled trial. Mov Disord. 2000 Jul; 15(4):678-82.
Score: 0.004
-
Expanding phenomenologic heterogeneity of tardive syndromes: Time for an updated assessment tool. Parkinsonism Relat Disord. 2020 08; 77:141-145.
Score: 0.004
-
The evolution of diagnosis in early Parkinson disease. Parkinson Study Group. Arch Neurol. 2000 Mar; 57(3):369-72.
Score: 0.004
-
Outcome measurement in functional neurological disorder: a systematic review and recommendations. J Neurol Neurosurg Psychiatry. 2020 06; 91(6):638-649.
Score: 0.004
-
Tardive and idiopathic oromandibular dystonia: a clinical comparison. J Neurol Neurosurg Psychiatry. 2000 Feb; 68(2):186-90.
Score: 0.004
-
Treating severe bruxism with botulinum toxin. J Am Dent Assoc. 2000 Feb; 131(2):211-6.
Score: 0.004
-
Postural Directionality and Head Tremor in Cervical Dystonia. Tremor Other Hyperkinet Mov (N Y). 2020; 10.
Score: 0.004
-
Essential tremor: clinical characteristics. Neurology. 2000; 54(11 Suppl 4):S21-5.
Score: 0.004
-
Complications and limitations of drug therapy for Parkinson's disease. Neurology. 2000; 55(12 Suppl 6):S2-6.
Score: 0.004
-
Genetic modifiers of risk and age at onset in GBA associated Parkinson's disease and Lewy body dementia. Brain. 2020 01 01; 143(1):234-248.
Score: 0.004
-
EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson's Disease. J Parkinsons Dis. 2020; 10(2):543-558.
Score: 0.004
-
Functional gait disorders, clinical phenomenology, and classification. Neurol Sci. 2020 Apr; 41(4):911-915.
Score: 0.004
-
Botulinum toxin A in patients with oromandibular dystonia: long-term follow-up. Neurology. 1999 Dec 10; 53(9):2102-7.
Score: 0.004
-
Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet Neurol. 2019 12; 18(12):1091-1102.
Score: 0.004
-
Essential tremor-plus: a controversial new concept. Lancet Neurol. 2020 03; 19(3):266-270.
Score: 0.004
-
Re-emergent tremor of Parkinson's disease. J Neurol Neurosurg Psychiatry. 1999 Nov; 67(5):646-50.
Score: 0.004
-
Bilineal transmission in Tourette syndrome. Neurology. 1999 Sep 11; 53(4):813-8.
Score: 0.004
-
Hypertension and progressive supranuclear palsy. Parkinsonism Relat Disord. 2019 09; 66:166-170.
Score: 0.004
-
Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol. Am J Psychiatry. 1999 Aug; 156(8):1279-81.
Score: 0.004
-
Levodopa-induced dyskinesias treated by pallidotomy. J Neurol Sci. 1999 Aug 01; 167(1):62-7.
Score: 0.004
-
Minimal clinically important change in patients with cervical dystonia: Results from the CD PROBE study. J Neurol Sci. 2019 Oct 15; 405:116413.
Score: 0.004
-
New and emerging therapies for Parkinson disease. Arch Neurol. 1999 Jul; 56(7):785-90.
Score: 0.004
-
A novel sublingual apomorphine treatment for patients with fluctuating Parkinson's disease. Mov Disord. 1999 Jul; 14(4):664-8.
Score: 0.004
-
Bruxism and cranial-cervical dystonia: is there a relationship? Cranio. 1999 Jul; 17(3):196-201.
Score: 0.004
-
Exercise performance in those having Parkinson's disease and healthy normals. Med Sci Sports Exerc. 1999 Jun; 31(6):761-6.
Score: 0.004
-
Autosomal dominant mitochondrial membrane protein-associated neurodegeneration (MPAN). Mol Genet Genomic Med. 2019 07; 7(7):e00736.
Score: 0.004
-
Practice guideline recommendations summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders. Neurology. 2019 05 07; 92(19):896-906.
Score: 0.004
-
Comprehensive systematic review summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders. Neurology. 2019 05 07; 92(19):907-915.
Score: 0.004
-
Head tremor at disease onset: an ataxic phenotype of cervical dystonia. J Neurol. 2019 Aug; 266(8):1844-1851.
Score: 0.004
-
Parkinson's disease age at onset genome-wide association study: Defining heritability, genetic loci, and a-synuclein mechanisms. Mov Disord. 2019 06; 34(6):866-875.
Score: 0.004
-
Bilateral hemifacial spasm: a report of five cases and a literature review. Mov Disord. 1999 Mar; 14(2):345-9.
Score: 0.004
-
Interrogating the Genetic Determinants of Tourette's Syndrome and Other Tic Disorders Through Genome-Wide Association Studies. Am J Psychiatry. 2019 03 01; 176(3):217-227.
Score: 0.004
-
Pathogenesis and pathophysiology of functional (psychogenic) movement disorders. Neurobiol Dis. 2019 07; 127:32-44.
Score: 0.004
-
Movement and reaction times and fine coordination tasks following pallidotomy. Mov Disord. 1999 Jan; 14(1):57-62.
Score: 0.004
-
Clinical correlates of vascular parkinsonism. Arch Neurol. 1999 Jan; 56(1):98-102.
Score: 0.004
-
Efficacy and tolerability of a novel sublingual apomorphine preparation in patients with fluctuating Parkinson's disease. Clin Neuropharmacol. 1999 Jan-Feb; 22(1):1-4.
Score: 0.004
-
Attitudes toward neurosurgical procedures for Parkinson's disease and obsessive-compulsive disorder. J Neuropsychiatry Clin Neurosci. 1999; 11(2):259-67.
Score: 0.004
-
Hemifacial spasm: clinical findings and treatment. Muscle Nerve. 1998 Dec; 21(12):1740-7.
Score: 0.004
-
Peripherally induced oromandibular dystonia. J Neurol Neurosurg Psychiatry. 1998 Nov; 65(5):722-8.
Score: 0.004
-
Predictors of alcohol responsiveness in dystonia. Neurology. 2018 11 20; 91(21):e2020-e2026.
Score: 0.004
-
Dystonia. Nat Rev Dis Primers. 2018 09 20; 4(1):25.
Score: 0.004
-
Ecopipam, a D1 receptor antagonist, for treatment of tourette syndrome in children: A randomized, placebo-controlled crossover study. Mov Disord. 2018 08; 33(8):1272-1280.
Score: 0.004
-
Benefits and risks of unilateral and bilateral ventral intermediate nucleus deep brain stimulation for axial essential tremor symptoms. Parkinsonism Relat Disord. 2019 03; 60:126-132.
Score: 0.004
-
Local field potentials of subthalamic nucleus contain electrophysiological footprints of motor subtypes of Parkinson's disease. Proc Natl Acad Sci U S A. 2018 09 04; 115(36):E8567-E8576.
Score: 0.004
-
Consensus for the measurement of the camptocormia angle in the standing patient. Parkinsonism Relat Disord. 2018 07; 52:1-5.
Score: 0.004
-
Mouse bioassay versus Western blot assay for botulinum toxin antibodies: correlation with clinical response. Neurology. 1998 Jun; 50(6):1624-9.
Score: 0.004
-
Post-traumatic movement disorders: effect of the legal system on outcome. J Forensic Sci. 1998 Mar; 43(2):334-9.
Score: 0.004
-
Lifetime exposure to estrogen and progressive supranuclear palsy: Environmental and Genetic PSP study. Mov Disord. 2018 03; 33(3):468-472.
Score: 0.004
-
The nosology of tardive syndromes. J Neurol Sci. 2018 06 15; 389:10-16.
Score: 0.004
-
Medical therapy and botulinum toxin in dystonia. Adv Neurol. 1998; 78:169-83.
Score: 0.004
-
Excessive burden of lysosomal storage disorder gene variants in Parkinson's disease. Brain. 2017 12 01; 140(12):3191-3203.
Score: 0.004
-
The Regions on the Light Chain of Botulinum Neurotoxin Type A Recognized by T Cells from Toxin-Treated Cervical Dystonia Patients. The Complete Human T-Cell Recognition Map of the Toxin Molecule. Immunol Invest. 2018 Jan; 47(1):18-39.
Score: 0.004
-
Tics secondary to craniocerebral trauma. Mov Disord. 1997 Sep; 12(5):776-82.
Score: 0.004
-
Treatable inherited rare movement disorders. Mov Disord. 2018 01; 33(1):21-35.
Score: 0.004
-
Influences of HLA DRB1, DQA1 and DQB1 on T-cell recognition of epitopes and of larger regions of the botulinum neurotoxin molecule. Immunol Lett. 2017 10; 190:257-264.
Score: 0.004
-
Safety of Converting From Tetrabenazine to Deutetrabenazine for the Treatment of Chorea. JAMA Neurol. 2017 08 01; 74(8):977-982.
Score: 0.004
-
[Tics and Tourette's syndrome]. Cas Lek Cesk. 1997 Jun 26; 136(13):399-404.
Score: 0.004
-
ADCY5-related movement disorders: Frequency, disease course and phenotypic variability in a cohort of paediatric patients. Parkinsonism Relat Disord. 2017 Aug; 41:37-43.
Score: 0.004
-
Tourette syndrome. Phenomenology and classification of tics. Neurol Clin. 1997 May; 15(2):267-75.
Score: 0.004
-
Hemidystonia secondary to carotid artery gunshot injury. Childs Nerv Syst. 1997 May; 13(5):285-8.
Score: 0.004
-
Psychiatric associations of adult-onset focal dystonia phenotypes. J Neurol Neurosurg Psychiatry. 2017 07; 88(7):595-602.
Score: 0.004
-
Thalamic DBS with a constant-current device in essential tremor: A?controlled clinical trial. Parkinsonism Relat Disord. 2017 Jul; 40:18-26.
Score: 0.004
-
Familial essential tremor in 4 kindreds. Prospects for genetic mapping. Arch Neurol. 1997 Mar; 54(3):289-94.
Score: 0.004
-
Are psychogenic non-epileptic seizures just another symptom of conversion disorder? J Neurol Neurosurg Psychiatry. 2017 05; 88(5):425-429.
Score: 0.004
-
Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology. 1997 Feb; 48(2):358-62.
Score: 0.004
-
Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial. JAMA Neurol. 2017 Feb 01; 74(2):216-224.
Score: 0.004
-
Improvement of parkinsonian signs after vascular lesions of the basal ganglia circuitry. Mov Disord. 1997 Jan; 12(1):124-6.
Score: 0.004
-
Thalamic surgery for movement disorders. Adv Neurol. 1997; 74:221-33.
Score: 0.004
-
[Medial posteroventral pallidotomy for the treatment of Parkinson's disease]. Zentralbl Neurochir. 1997; 58(4):153-62.
Score: 0.004
-
Botulinum toxin: historical perspective and potential new indications. Muscle Nerve Suppl. 1997; 6:S129-45.
Score: 0.004
-
Understanding falls in progressive supranuclear palsy. Parkinsonism Relat Disord. 2017 02; 35:75-81.
Score: 0.003
-
A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease. Neurology. 2017 Jan 10; 88(2):152-159.
Score: 0.003
-
Restless legs syndrome: clinicoetiologic correlates. Neurology. 1996 Dec; 47(6):1435-41.
Score: 0.003
-
Genome-wide association study in essential tremor identifies three new loci. Brain. 2016 12; 139(Pt 12):3163-3169.
Score: 0.003
-
Surgical treatment of Parkinson's disease. Am Fam Physician. 1996 Oct; 54(5):1621-9.
Score: 0.003
-
Submolecular recognition regions of the HN domain of the heavy chain of botulinum neurotoxin type A by T cells from toxin-treated cervical dystonia patients. J Neuroimmunol. 2016 11 15; 300:36-46.
Score: 0.003
-
"Complex" dystonia is not a category in the new 2013 consensus classification. Mov Disord. 2016 11; 31(11):1758-1759.
Score: 0.003
-
Severe motor tics causing cervical myelopathy in Tourette's syndrome. Mov Disord. 1996 Sep; 11(5):563-6.
Score: 0.003
-
Propofol-induced dyskinesias in Parkinson's disease. Anesth Analg. 1996 Aug; 83(2):420-22.
Score: 0.003
-
Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial. JAMA. 2016 Jul 05; 316(1):40-50.
Score: 0.003
-
Cervical dystonia as the initial presentation of Huntington's disease. Mov Disord. 1996 Jul; 11(4):457-9.
Score: 0.003
-
Identification of TMEM230 mutations in familial Parkinson's disease. Nat Genet. 2016 07; 48(7):733-9.
Score: 0.003
-
A randomized, double-blind, placebo-controlled study to evaluate botulinum toxin type A in essential hand tremor. Mov Disord. 1996 May; 11(3):250-6.
Score: 0.003
-
Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache [RETIRED]: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016 05 10; 86(19):1818-26.
Score: 0.003
-
Clinimetric testing of the comprehensive cervical dystonia rating scale. Mov Disord. 2016 Apr; 31(4):563-9.
Score: 0.003
-
Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials. JAMA Neurol. 2016 Jan; 73(1):102-10.
Score: 0.003
-
Whole-Exome Sequencing in Familial Parkinson Disease. JAMA Neurol. 2016 Jan; 73(1):68-75.
Score: 0.003
-
Delayed-onset progressive movement disorders after static brain lesions. Neurology. 1996 Jan; 46(1):68-74.
Score: 0.003
-
Submolecular recognition of the C-terminal domain of the heavy chain of botulinum neurotoxin type A by T cells from toxin-treated cervical dystonia patients. Immunobiology. 2016 Apr; 221(4):568-76.
Score: 0.003
-
Movement Disorders From the Use of Metoclopramide and Other Antiemetics in the Treatment of Migraine. Headache. 2016 Jan; 56(1):153-61.
Score: 0.003
-
Paroxysmal dyskinesias: clinical features and classification. Ann Neurol. 1995 Oct; 38(4):571-9.
Score: 0.003
-
Outcome after stereotactic thalamotomy for parkinsonian, essential, and other types of tremor. Neurosurgery. 1995 Oct; 37(4):680-6; discussion 686-7.
Score: 0.003
-
Response and immunoresistance to botulinum toxin injections. Neurology. 1995 Sep; 45(9):1743-6.
Score: 0.003
-
International Classification of Diseases, tenth revision: neurological adaptation (ICD-10 NA): extrapyramidal and movement disorders. Mov Disord. 1995 Sep; 10(5):533-40.
Score: 0.003
-
Diffusion imaging of nigral alterations in early Parkinson's disease with dopaminergic deficits. Mov Disord. 2015 Dec; 30(14):1885-92.
Score: 0.003
-
Emotional and functional impact of DNA testing on patients with symptoms of Huntington's disease. J Med Genet. 1995 Jul; 32(7):516-8.
Score: 0.003
-
Rotenone affects p53 transcriptional activity and apoptosis via targeting SIRT1 and H3K9 acetylation in SH-SY5Y cells. J Neurochem. 2015 Aug; 134(4):668-76.
Score: 0.003
-
Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial. Ann Neurol. 2015 Aug; 78(2):248-57.
Score: 0.003
-
A Pilot Study of a Cognitive-Behavioral Treatment for Anxiety and Depression in Patients With Parkinson Disease. J Geriatr Psychiatry Neurol. 2015 Sep; 28(3):210-7.
Score: 0.003
-
Tardive syndromes and other drug-induced movement disorders. Clin Neuropharmacol. 1995 Jun; 18(3):197-214.
Score: 0.003
-
Natural history of multiple system atrophy in the USA: a prospective cohort study. Lancet Neurol. 2015 Jul; 14(7):710-9.
Score: 0.003
-
Tremor and longevity in relatives of patients with Parkinson's disease, essential tremor, and control subjects. Neurology. 1995 Apr; 45(4):645-8.
Score: 0.003
-
Clinical and pharmacological properties of incobotulinumtoxinA and its use in neurological disorders. Drug Des Devel Ther. 2015; 9:1913-26.
Score: 0.003
-
Peripherally induced tremor and parkinsonism. Arch Neurol. 1995 Mar; 52(3):263-70.
Score: 0.003
-
Tourettism associated with Huntington's disease. Mov Disord. 1995 Jan; 10(1):103-5.
Score: 0.003
-
Epigenetic mechanisms in Parkinson's disease. J Neurol Sci. 2015 Feb 15; 349(1-2):3-9.
Score: 0.003
-
Myorhythmia: phenomenology, etiology, and treatment. Mov Disord. 2015 Feb; 30(2):171-9.
Score: 0.003
-
Post-traumatic movement disorders: central and peripheral mechanisms. Neurology. 1994 Nov; 44(11):2006-14.
Score: 0.003
-
Cross-disorder genome-wide analyses suggest a complex genetic relationship between Tourette's syndrome and OCD. Am J Psychiatry. 2015 Jan; 172(1):82-93.
Score: 0.003
-
IncobotulinumtoxinA (Xeomin?) injected for blepharospasm or cervical dystonia according to patient needs is well tolerated. J Neurol Sci. 2014 Nov 15; 346(1-2):116-20.
Score: 0.003
-
Botulinum toxin in movement disorders. Curr Opin Neurol. 1994 Aug; 7(4):358-66.
Score: 0.003
-
Neuroprotection by Orexin-A via HIF-1a induction in a cellular model of Parkinson's disease. Neurosci Lett. 2014 Sep 05; 579:35-40.
Score: 0.003
-
Copy number variation in obsessive-compulsive disorder and tourette syndrome: a cross-disorder study. J Am Acad Child Adolesc Psychiatry. 2014 Aug; 53(8):910-9.
Score: 0.003
-
Neurohistopathological findings at the electrode-tissue interface in long-term deep brain stimulation: systematic literature review, case report, and assessment of stimulation threshold safety. Neuromodulation. 2014 Jul; 17(5):405-18; discussion 418.
Score: 0.003
-
CAG repeat size and clinical presentation in Huntington's disease. Neurology. 1994 Jun; 44(6):1137-43.
Score: 0.003
-
Peptidoglycan recognition protein genes and risk of Parkinson's disease. Mov Disord. 2014 Aug; 29(9):1171-80.
Score: 0.003
-
Alleviating manoeuvres (sensory tricks) in cervical dystonia. J Neurol Neurosurg Psychiatry. 2014 Aug; 85(8):882-4.
Score: 0.003
-
Botulinum toxin in the treatment of dystonic tics. Mov Disord. 1994 May; 9(3):347-9.
Score: 0.003
-
Cervical dystonia and pain: characteristics and treatment patterns from CD PROBE (Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy). J Neurol. 2014 Jul; 261(7):1309-19.
Score: 0.003
-
Reply: dystonia after severe head injuries. Mov Disord. 2014 Apr; 29(4):578-9.
Score: 0.003
-
Vascular progressive supranuclear palsy. J Neural Transm Suppl. 1994; 42:189-201.
Score: 0.003
-
Designing clinical trials for dystonia. Neurotherapeutics. 2014 Jan; 11(1):117-27.
Score: 0.003
-
Sensory aspects of movement disorders. Lancet Neurol. 2014 Jan; 13(1):100-12.
Score: 0.003
-
Partitioning the heritability of Tourette syndrome and obsessive compulsive disorder reveals differences in genetic architecture. PLoS Genet. 2013 Oct; 9(10):e1003864.
Score: 0.003
-
The safety and efficacy of thalamic deep brain stimulation in essential tremor: 10 years and beyond. J Neurol Neurosurg Psychiatry. 2014 May; 85(5):567-72.
Score: 0.003
-
What is it? Case 1, 1993: parkinsonism, dysautonomia, and ophthalmoparesis. Mov Disord. 1993 Oct; 8(4):525-32.
Score: 0.003
-
Bilateral pallidal deep brain stimulation for X-linked dystonia-parkinsonism. World Neurosurg. 2014 Jul-Aug; 82(1-2):241.e1-4.
Score: 0.003
-
Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease. Parkinsonism Relat Disord. 2014 Feb; 20(2):142-8.
Score: 0.003
-
Use of botulinum toxin in the treatment of hand dystonia. J Hand Surg Am. 1993 Sep; 18(5):883-7.
Score: 0.003
-
Hereditary motor-sensory neuropathy and movement disorders. Muscle Nerve. 1993 Sep; 16(9):904-10.
Score: 0.003
-
Diffusion, spread, and migration of botulinum toxin. Mov Disord. 2013 Nov; 28(13):1775-83.
Score: 0.003
-
Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine. Am J Med. 1993 Jul; 95(1):38-48.
Score: 0.003
-
Phenomenology and classification of dystonia: a consensus update. Mov Disord. 2013 Jun 15; 28(7):863-73.
Score: 0.003
-
Tardive stereotypy and other movement disorders in tardive dyskinesias. Neurology. 1993 May; 43(5):937-41.
Score: 0.003
-
Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS. Neurology. 2013 May 28; 80(22):2022-7.
Score: 0.003
-
Movement disorders in systemic lupus erythematosus and the antiphospholipid syndrome. J Neural Transm (Vienna). 2013 Nov; 120(11):1579-89.
Score: 0.003
-
Longitudinal experience with botulinum toxin injections for treatment of blepharospasm and cervical dystonia. Neurology. 1993 Apr; 43(4):834-6.
Score: 0.003
-
Cocaine-related movement disorders. Mov Disord. 1993 Apr; 8(2):175-8.
Score: 0.003
-
Deprenyl in attention deficit associated with Tourette's syndrome. Arch Neurol. 1993 Mar; 50(3):286-8.
Score: 0.003
-
Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin(?)) injections in blepharospasm. J Neural Transm (Vienna). 2013 Sep; 120(9):1345-53.
Score: 0.003
-
How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society unified Parkinson's disease rating scale: comparison with the unified Parkinson's disease rating scale. Mov Disord. 2013 May; 28(5):668-70.
Score: 0.003
-
The spectrum of movement disorders in children with anti-NMDA receptor encephalitis. Mov Disord. 2013 Apr; 28(4):543-7.
Score: 0.003
-
Psychogenic myoclonus. Neurology. 1993 Feb; 43(2):349-52.
Score: 0.003
-
Evidence-based review and assessment of botulinum neurotoxin for the treatment of secretory disorders. Toxicon. 2013 Jun 01; 67:141-52.
Score: 0.003
-
Reliability of a new scale for essential tremor. Mov Disord. 2012 Oct; 27(12):1567-9.
Score: 0.003
-
Globus pallidus deep brain stimulation for refractory idiopathic restless legs syndrome. Sleep Med. 2012 Oct; 13(9):1202-4.
Score: 0.003
-
The alien hand and related signs. J Neurol Neurosurg Psychiatry. 1992 Sep; 55(9):806-10.
Score: 0.003
-
Mutation screening of the HTR2B gene in patients with Tourette syndrome. Neurosci Lett. 2012 Sep 27; 526(2):150-3.
Score: 0.003
-
Emerging therapies for Parkinson's disease. Curr Opin Neurol. 2012 Aug; 25(4):448-59.
Score: 0.003
-
Deep brain stimulation hardware complications in patients with movement disorders: risk factors and clinical correlations. Stereotact Funct Neurosurg. 2012; 90(5):300-6.
Score: 0.003
-
Early diagnosis and therapy of Parkinson's disease: can disease progression be curbed? J Neural Transm (Vienna). 2013 Jan; 120(1):197-210.
Score: 0.003
-
Deep brain stimulation for Tourette syndrome: target selection. Stereotact Funct Neurosurg. 2012; 90(4):213-24.
Score: 0.003
-
Chorea and ballism. Curr Opin Neurol Neurosurg. 1992 Jun; 5(3):308-13.
Score: 0.003
-
Alternating verbal fluency performance following bilateral subthalamic nucleus deep brain stimulation for Parkinson's disease. Eur J Neurol. 2012 Dec; 19(12):1525-31.
Score: 0.003
-
Low body weight in Parkinson's disease. South Med J. 1992 Apr; 85(4):351-4.
Score: 0.003
-
Acoustic reflex abnormalities in cranial-cervical dystonia. Neurology. 1992 Mar; 42(3 Pt 1):594-7.
Score: 0.003
-
A mechanistic study of proteasome inhibition-induced iron misregulation in dopamine neuron degeneration. Neurosignals. 2012; 20(4):223-36.
Score: 0.002
-
Iron dysregulation in movement disorders. Neurobiol Dis. 2012 Apr; 46(1):1-18.
Score: 0.002
-
Subthalamic deep brain stimulation with a constant-current device in Parkinson's disease: an open-label randomised controlled trial. Lancet Neurol. 2012 Feb; 11(2):140-9.
Score: 0.002
-
Tardive tremor. Mov Disord. 1992; 7(1):53-7.
Score: 0.002
-
Diagnosis and classification of tics and Tourette syndrome. Adv Neurol. 1992; 58:7-14.
Score: 0.002
-
Persistent dystonia possibly induced by flecainide. Mov Disord. 1992; 7(1):62-3.
Score: 0.002
-
Head injury, a-synuclein Rep1, and Parkinson's disease. Ann Neurol. 2012 Jan; 71(1):40-8.
Score: 0.002
-
Mutations in the gene PRRT2 cause paroxysmal kinesigenic dyskinesia with infantile convulsions. Cell Rep. 2012 Jan 26; 1(1):2-12.
Score: 0.002
-
Perampanel, an AMPA antagonist, found to have no benefit in reducing "off" time in Parkinson's disease. Mov Disord. 2012 Feb; 27(2):284-8.
Score: 0.002
-
Clinical correlates of response to botulinum toxin injections. Arch Neurol. 1991 Dec; 48(12):1253-6.
Score: 0.002
-
Human T-cell responses to botulinum neurotoxin. Responses in vitro of lymphocytes from patients with cervical dystonia and/or other movement disorders treated with BoNT/A or BoNT/B. J Neuroimmunol. 2011 Dec 15; 240-241:121-8.
Score: 0.002
-
Reflexive and volitional saccades: biomarkers of Huntington disease severity and progression. J Neurol Sci. 2012 Feb 15; 313(1-2):35-41.
Score: 0.002
-
Molecular immune recognition of botulinum neurotoxin B. The light chain regions that bind human blocking antibodies from toxin-treated cervical dystonia patients. Antigenic structure of the entire BoNT/B molecule. Immunobiology. 2012 Jan; 217(1):17-27.
Score: 0.002
-
The coexistence of tics and dystonia. Arch Neurol. 1991 Aug; 48(8):862-5.
Score: 0.002
-
Resveratrol-activated AMPK/SIRT1/autophagy in cellular models of Parkinson's disease. Neurosignals. 2011; 19(3):163-74.
Score: 0.002
-
Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN?, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. J Neurol Sci. 2011 Sep 15; 308(1-2):103-9.
Score: 0.002
-
Human T-cell responses to botulinum neurotoxin: proliferative responses in vitro of lymphocytes from botulinum neurotoxin A-treated movement disorder patients. J Neuroimmunol. 2011 Aug 15; 237(1-2):66-72.
Score: 0.002
-
Cervical dystonia: clinical findings and associated movement disorders. Neurology. 1991 Jul; 41(7):1088-91.
Score: 0.002
-
Diagnosis and treatment of complications related to deep brain stimulation hardware. Mov Disord. 2011 Jul; 26(8):1398-406.
Score: 0.002
-
Changes in cognitive-emotional and physiological symptoms of depression following STN-DBS for the treatment of Parkinson's disease. Eur J Neurol. 2012 Jan; 19(1):121-7.
Score: 0.002
-
Flu-like symptoms following botulinum toxin therapy. Toxicon. 2011 Jul; 58(1):1-7.
Score: 0.002
-
Essential tremor quantification during activities of daily living. Parkinsonism Relat Disord. 2011 Aug; 17(7):537-42.
Score: 0.002
-
Therapeutic uses of botulinum toxin. N Engl J Med. 1991 Apr 25; 324(17):1186-94.
Score: 0.002
-
Peripheral trauma and movement disorders: a systematic review of reported cases. J Neurol Neurosurg Psychiatry. 2011 Aug; 82(8):892-8.
Score: 0.002
-
A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol. 2011 May; 10(5):415-23.
Score: 0.002
-
Systematic genetic analysis of the PITX3 gene in patients with Parkinson disease. Mov Disord. 2011 Aug 01; 26(9):1729-32.
Score: 0.002
-
Complement 3 and factor h in human cerebrospinal fluid in Parkinson's disease, Alzheimer's disease, and multiple-system atrophy. Am J Pathol. 2011 Apr; 178(4):1509-16.
Score: 0.002
-
Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol. 2011 Mar; 69(3):570-80.
Score: 0.002
-
Cognitive outcome and reliable change indices two years following bilateral subthalamic nucleus deep brain stimulation. Parkinsonism Relat Disord. 2011 Jun; 17(5):321-7.
Score: 0.002
-
Essential tremor: clinical correlates in 350 patients. Neurology. 1991 Feb; 41(2 ( Pt 1)):234-8.
Score: 0.002
-
Dystonic tics in patients with Tourette's syndrome. Mov Disord. 1991; 6(3):248-52.
Score: 0.002
-
Stiff-person syndrome: an autoimmune disease. Mov Disord. 1991; 6(1):12-20.
Score: 0.002
-
Orthostatic tremor: an association with essential tremor. Mov Disord. 1991; 6(1):60-4.
Score: 0.002
-
Regions of botulinum neurotoxin A light chain recognized by human anti-toxin antibodies from cervical dystonia patients immunoresistant to toxin treatment. The antigenic structure of the active toxin recognized by human antibodies. Immunobiology. 2011 Jul; 216(7):782-92.
Score: 0.002
-
Iron chelation and neuroprotection in neurodegenerative diseases. J Neural Transm (Vienna). 2011 Mar; 118(3):473-7.
Score: 0.002
-
CSF A?(42) and tau in Parkinson's disease with cognitive impairment. Mov Disord. 2010 Nov 15; 25(15):2682-5.
Score: 0.002
-
The association of Tourette syndrome and dopa-responsive dystonia. Mov Disord. 2011 Feb 01; 26(2):359-60.
Score: 0.002
-
Dramatic response of facial stereotype/tic to tetrabenazine in the first reported cases of neuroferritinopathy in the United States. Mov Disord. 2010 Oct 30; 25(14):2470-2.
Score: 0.002
-
Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol. 2010 Dec; 9(12):1164-1172.
Score: 0.002
-
LINGO1 rs9652490 variant in Parkinson disease patients. Neurosci Lett. 2011 Jan 07; 487(2):174-6.
Score: 0.002
-
Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology. 1990 Oct; 40(10):1529-34.
Score: 0.002
-
Association of HLA Class II alleles and haplotypes with cervical dystonia: HLA DR13-DQ6 (DQB1*0604) homozygotes are at greatly increased risk of cervical dystonia in Caucasian Americans. Autoimmunity. 2011 May; 44(3):167-76.
Score: 0.002
-
Tardive dyskinesia and other movement disorders secondary to aripiprazole. Mov Disord. 2011 Jan; 26(1):147-52.
Score: 0.002
-
Nonlinear temporal organization of neuronal discharge in the basal ganglia of Parkinson's disease patients. Exp Neurol. 2010 Aug; 224(2):542-4.
Score: 0.002
-
Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm. J Neurol Neurosurg Psychiatry. 1990 Aug; 53(8):633-9.
Score: 0.002
-
Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol. 2010 Jul; 68(1):18-27.
Score: 0.002
-
Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease. Neurosci Lett. 2010 Aug 09; 480(1):78-82.
Score: 0.002
-
Neuroprotection of deferoxamine on rotenone-induced injury via accumulation of HIF-1 alpha and induction of autophagy in SH-SY5Y cells. Neurochem Int. 2010 Oct; 57(3):198-205.
Score: 0.002
-
Multiple LRRK2 variants modulate risk of Parkinson disease: a Chinese multicenter study. Hum Mutat. 2010 May; 31(5):561-8.
Score: 0.002
-
Neurologic approach to drug-induced movement disorders: a study of 125 patients. South Med J. 1990 May; 83(5):525-32.
Score: 0.002
-
LINGO1 and LINGO2 variants are associated with essential tremor and Parkinson disease. Neurogenetics. 2010 Oct; 11(4):401-8.
Score: 0.002
-
Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat Disord. 2010 Jun; 16(5):316-23.
Score: 0.002
-
DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain. 2010 Mar; 133(Pt 3):713-26.
Score: 0.002
-
Botulinum toxin injections for cervical dystonia. Neurology. 1990 Feb; 40(2):277-80.
Score: 0.002
-
Long-term deep brain stimulation for essential tremor: 12-year clinicopathologic follow-up. Mov Disord. 2010 Jan 30; 25(2):232-8.
Score: 0.002
-
Sulpiride-induced tardive dystonia. Mov Disord. 1990; 5(1):83-4.
Score: 0.002
-
Progressive supranuclear palsy: motor, neurobehavioral, and neuro-ophthalmic findings. Adv Neurol. 1990; 53:293-304.
Score: 0.002
-
Glycoproteomics in neurodegenerative diseases. Mass Spectrom Rev. 2010 Jan-Feb; 29(1):79-125.
Score: 0.002
-
Tardive oculogyric crises. Neurology. 1989 Nov; 39(11):1434-7.
Score: 0.002
-
Metoclopramide-induced movement disorders. Clinical findings with a review of the literature. Arch Intern Med. 1989 Nov; 149(11):2486-92.
Score: 0.002
-
A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med. 2009 Sep 24; 361(13):1268-78.
Score: 0.002
-
Occupation and risk of parkinsonism: a multicenter case-control study. Arch Neurol. 2009 Sep; 66(9):1106-13.
Score: 0.002
-
Clinical, biochemical, and neuropathologic findings following transplantation of adrenal medulla to the caudate nucleus for treatment of Parkinson's disease. Neurology. 1989 Sep; 39(9):1227-34.
Score: 0.002
-
Rapamycin protects against rotenone-induced apoptosis through autophagy induction. Neuroscience. 2009 Dec 01; 164(2):541-51.
Score: 0.002
-
Hemiballism-hemichorea. Clinical and pharmacologic findings in 21 patients. Arch Neurol. 1989 Aug; 46(8):862-7.
Score: 0.002
-
The course of depressive symptoms in early Parkinson's disease. Mov Disord. 2009 Jul 15; 24(9):1306-11.
Score: 0.002
-
Dystonia in musicians. Semin Neurol. 1989 Jun; 9(2):131-5.
Score: 0.002
-
Safety of MRI in patients with implanted deep brain stimulation devices. Neuroimage. 2009 Aug; 47 Suppl 2:T53-7.
Score: 0.002
-
Lrrk2 R1441G-related Parkinson's disease: evidence of a common founding event in the seventh century in Northern Spain. Neurogenetics. 2009 Oct; 10(4):347-53.
Score: 0.002
-
GIGYF2 Asn56Ser and Asn457Thr mutations in Parkinson disease patients. Neurosci Lett. 2009 May 01; 454(3):209-11.
Score: 0.002
-
Parkinsonism-plus syndromes. Mov Disord. 1989; 4 Suppl 1:S95-119.
Score: 0.002
-
Comparison of Sinemet CR4 and standard Sinemet: double blind and long-term open trial in parkinsonian patients with fluctuations. Mov Disord. 1989; 4(4):303-9.
Score: 0.002
-
Lower body parkinsonism: evidence for vascular etiology. Mov Disord. 1989; 4(3):249-60.
Score: 0.002
-
Coprophenomena in Tourette syndrome. Dev Med Child Neurol. 2009 Mar; 51(3):218-27.
Score: 0.002
-
Dystonia and tremor induced by peripheral trauma: predisposing factors. J Neurol Neurosurg Psychiatry. 1988 Dec; 51(12):1512-9.
Score: 0.002
-
A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics. Mov Disord. 2008 Nov 15; 23(15):2194-201.
Score: 0.002
-
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008 Nov 15; 23(15):2129-70.
Score: 0.002
-
Update on blepharospasm: report from the BEBRF International Workshop. Neurology. 2008 Oct 14; 71(16):1275-82.
Score: 0.002
-
Neutralizing antibodies in dystonic patients who still respond well to botulinum toxin type A. Neurology. 2008 Sep 23; 71(13):1040; author reply 1040-1.
Score: 0.002
-
Molecular recognition of botulinum neurotoxin B heavy chain by human antibodies from cervical dystonia patients that develop immunoresistance to toxin treatment. Mol Immunol. 2008 Sep; 45(15):3878-88.
Score: 0.002
-
Parkinson's disease: recent advances in therapy. South Med J. 1988 Aug; 81(8):1021-7.
Score: 0.002
-
Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord. 2008 Jul 30; 23(10):1353-60.
Score: 0.002
-
Five-year follow-up of unilateral posteroventral pallidotomy in Parkinson's disease. Surg Neurol. 2009 May; 71(5):551-8.
Score: 0.002
-
Nurr1 deficiency predisposes to lactacystin-induced dopaminergic neuron injury in vitro and in vivo. Brain Res. 2008 Jul 30; 1222:222-9.
Score: 0.002
-
Lesch-Nyhan syndrome: a study of motor behavior and cerebrospinal fluid neurotransmitters. Ann Neurol. 1988 May; 23(5):466-9.
Score: 0.002
-
Role of botulinum toxin in the treatment of cervical dystonia. Neurol Clin. 2008 May; 26 Suppl 1:43-53.
Score: 0.002
-
Focal task-specific tremor and dystonia: categorization of occupational movement disorders. Neurology. 1988 Apr; 38(4):522-7.
Score: 0.002
-
CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol. 2008 Apr; 129(4):526-9.
Score: 0.002
-
Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias. Neurology. 1988 Mar; 38(3):391-4.
Score: 0.002
-
Application of targeted quantitative proteomics analysis in human cerebrospinal fluid using a liquid chromatography matrix-assisted laser desorption/ionization time-of-flight tandem mass spectrometer (LC MALDI TOF/TOF) platform. J Proteome Res. 2008 Feb; 7(2):720-30.
Score: 0.002
-
Tardive dystonia in patients with Tourette's syndrome. Mov Disord. 1988; 3(3):274-80.
Score: 0.002
-
Blepharospasm and oromandibular-laryngeal-cervical dystonia: a controlled trial of botulinum A toxin therapy. Adv Neurol. 1988; 50:583-91.
Score: 0.002
-
Case 3, 1988. Progressive myoclonic epilepsy, dementia, and blindness in a young girl. Mov Disord. 1988; 3(4):362-9.
Score: 0.002
-
Rett syndrome: qualitative and quantitative differentiation from autism. J Child Neurol. 1988; 3 Suppl:S65-7.
Score: 0.002
-
Case 2, 1988. Congenital mental retardation and juvenile parkinsonism. Mov Disord. 1988; 3(4):352-61.
Score: 0.002
-
Cranial-cervical dyskinesias: an overview. Adv Neurol. 1988; 49:1-13.
Score: 0.002
-
Etiology and differential diagnosis of blepharospasm and oromandibular dystonia. Adv Neurol. 1988; 49:103-16.
Score: 0.002
-
Orofacial and other self-mutilations. Adv Neurol. 1988; 49:365-81.
Score: 0.002
-
Botulinum A toxin in the treatment of blepharospasm. Adv Neurol. 1988; 49:467-72.
Score: 0.002
-
Blepharospasm and cranial-cervical dystonia (Meige's syndrome): familial occurrence. Adv Neurol. 1988; 49:117-23.
Score: 0.002
-
Depressed mood and memory impairment before and after unilateral posteroventral pallidotomy in Parkinson's disease. J Neuropsychiatry Clin Neurosci. 2008; 20(3):357-63.
Score: 0.002
-
Coexistent tardive dyskinesia and parkinsonism. Clin Neuropharmacol. 1987 Dec; 10(6):511-21.
Score: 0.002
-
Potential outcome measures and trial design issues for multiple system atrophy. Mov Disord. 2007 Dec; 22(16):2371-7.
Score: 0.002
-
Motor, behavioral and pharmacologic findings in Tourette's syndrome. Can J Neurol Sci. 1987 Aug; 14(3 Suppl):541-6.
Score: 0.002
-
Short and long-term motor and cognitive outcome of staged bilateral pallidotomy: a retrospective analysis. Acta Neurochir (Wien). 2007; 149(9):857-66; discussion 866.
Score: 0.002
-
The impact of depressive symptoms in early Parkinson disease. Neurology. 2007 Jul 24; 69(4):342-7.
Score: 0.002
-
A founding LRRK2 haplotype shared by Tunisian, US, European and Middle Eastern families with Parkinson's disease. Parkinsonism Relat Disord. 2008; 14(1):77-80.
Score: 0.002
-
G2019S mutation in the leucine-rich repeat kinase 2 gene is not associated with multiple system atrophy. Mov Disord. 2007 Mar 15; 22(4):546-9.
Score: 0.002
-
Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology. 2007 Jan 23; 68(4):272-6.
Score: 0.002
-
Tardive myoclonus. Mov Disord. 1987; 2(4):307-11.
Score: 0.002
-
Blepharospasm and autoimmune diseases. Mov Disord. 1987; 2(3):159-63.
Score: 0.002
-
A peptide-based immunoassay for antibodies against botulinum neurotoxin A. J Mol Recognit. 2007 Jan-Feb; 20(1):15-21.
Score: 0.002
-
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord. 2007 Jan; 22(1):41-7.
Score: 0.002
-
Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson's disease families. Mov Disord. 2007 Jan; 22(1):55-61.
Score: 0.002
-
Patient selection and assessment recommendations for deep brain stimulation in Tourette syndrome. Mov Disord. 2006 Nov; 21(11):1831-8.
Score: 0.002
-
Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis. 2006 Aug; 9(3):293-348.
Score: 0.002
-
Drug-induced dystonia in neuronal ceroid-lipofuscinosis. Pediatr Neurol. 1986 Jul-Aug; 2(4):236-7.
Score: 0.002
-
Genomewide scans in North American families reveal genetic linkage of essential tremor to a region on chromosome 6p23. Brain. 2006 Sep; 129(Pt 9):2318-31.
Score: 0.002
-
Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A. Mol Immunol. 2007 Feb; 44(5):1029-41.
Score: 0.002
-
Contemporary assessment and pharmacotherapy of Tourette syndrome. NeuroRx. 2006 Apr; 3(2):192-206.
Score: 0.002
-
HS1-BP3 gene variant is common in familial essential tremor. Mov Disord. 2006 Mar; 21(3):306-9.
Score: 0.002
-
Topiramate in essential tremor: a double-blind, placebo-controlled trial. Neurology. 2006 Mar 14; 66(5):672-7.
Score: 0.002
-
Nurr1 in Parkinson's disease and related disorders. J Comp Neurol. 2006 Jan 20; 494(3):495-514.
Score: 0.002
-
The phenomenology of tics. Mov Disord. 1986; 1(1):17-26.
Score: 0.002
-
Parkinsonism and acquired hydrocephalus. Mov Disord. 1986; 1(1):59-64.
Score: 0.002
-
Valproic acid-mediated Hsp70 induction and anti-apoptotic neuroprotection in SH-SY5Y cells. FEBS Lett. 2005 Dec 19; 579(30):6716-20.
Score: 0.002
-
Small interfering RNA targeting the PINK1 induces apoptosis in dopaminergic cells SH-SY5Y. Biochem Biophys Res Commun. 2005 Dec 02; 337(4):1133-8.
Score: 0.002
-
Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord. 2005 Jul; 20(7):783-91.
Score: 0.002
-
Biological effects of pramipexole on dopaminergic neuron-associated genes: relevance to neuroprotection. Neurosci Lett. 2005 Mar 29; 377(2):106-9.
Score: 0.002
-
Examination of the SGCE gene in Tourette syndrome patients with obsessive-compulsive disorder. Mov Disord. 2004 Oct; 19(10):1237-8.
Score: 0.001
-
Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol. 2004 Jul; 61(7):1044-53.
Score: 0.001
-
Apolipoprotein E controls the risk and age at onset of Parkinson disease. Neurology. 2004 Jun 08; 62(11):2005-9.
Score: 0.001
-
Effects of visual and auditory cues on gait in individuals with Parkinson's disease. J Neurol Sci. 2004 Apr 15; 219(1-2):63-9.
Score: 0.001
-
Dopaminergic properties and experimental anti-parkinsonian effects of IPX750 in rodent models of Parkinson disease. Clin Neuropharmacol. 2004 Mar-Apr; 27(2):63-73.
Score: 0.001
-
Clinical gait and balance scale (GABS): validation and utilization. J Neurol Sci. 2004 Jan 15; 217(1):89-99.
Score: 0.001
-
Phenotypic features of Huntington's disease-like 2. Mov Disord. 2003 Dec; 18(12):1527-30.
Score: 0.001
-
Glutathione S-transferase omega-1 modifies age-at-onset of Alzheimer disease and Parkinson disease. Hum Mol Genet. 2003 Dec 15; 12(24):3259-67.
Score: 0.001
-
Treatment of hypophonia with collagen vocal cord augmentation in patients with parkinsonism. Mov Disord. 2003 Oct; 18(10):1190-2.
Score: 0.001
-
Association study of Parkin gene polymorphisms with idiopathic Parkinson disease. Arch Neurol. 2003 Jul; 60(7):975-80.
Score: 0.001
-
Haplotype analysis of the ETM2 locus in familial essential tremor. Neurogenetics. 2003 Aug; 4(4):185-9.
Score: 0.001
-
A heteroplasmic mitochondrial complex I gene mutation in adult-onset dystonia. Neurogenetics. 2003 Aug; 4(4):199-205.
Score: 0.001
-
Genetic polymorphisms of the N-acetyltransferase genes and risk of Parkinson's disease. Neurology. 2003 Apr 08; 60(7):1189-91.
Score: 0.001
-
Screening for mutations in the MECP2 (Rett syndrome) gene in Gilles de la Tourette syndrome. Arch Neurol. 2003 Apr; 60(4):502-3.
Score: 0.001
-
Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease. Am J Hum Genet. 2003 Apr; 72(4):804-11.
Score: 0.001
-
Substantia nigra lesions in viral encephalitis. Mov Disord. 2003 Feb; 18(2):213-6.
Score: 0.001
-
Benefits and risks of pharmacological treatments for essential tremor. Drug Saf. 2003; 26(7):461-81.
Score: 0.001
-
Potential therapeutic properties of green tea polyphenols in Parkinson's disease. Drugs Aging. 2003; 20(10):711-21.
Score: 0.001
-
Mutations in NR4A2 associated with familial Parkinson disease. Nat Genet. 2003 Jan; 33(1):85-9.
Score: 0.001
-
Cross reaction of tetanus and botulinum neurotoxins A and B and the boosting effect of botulinum neurotoxins A and B on a primary anti-tetanus antibody response. Immunol Invest. 2002 Aug-Nov; 31(3-4):247-62.
Score: 0.001
-
Association of homozygous 7048G7049 variant in the intron six of Nurr1 gene with Parkinson's disease. Neurology. 2002 Mar 26; 58(6):881-4.
Score: 0.001
-
Age at onset in two common neurodegenerative diseases is genetically controlled. Am J Hum Genet. 2002 Apr; 70(4):985-93.
Score: 0.001
-
Intrafamilial phenotypic variability of the DYT1 dystonia: from asymptomatic TOR1A gene carrier status to dystonic storm. Mov Disord. 2002 Mar; 17(2):339-45.
Score: 0.001
-
Complete genomic screen in Parkinson disease: evidence for multiple genes. JAMA. 2001 Nov 14; 286(18):2239-44.
Score: 0.001
-
Association of single-nucleotide polymorphisms of the tau gene with late-onset Parkinson disease. JAMA. 2001 Nov 14; 286(18):2245-50.
Score: 0.001
-
Identification of a high frequency of mutation at exon 8 of the ATP7B gene in a Chinese population with Wilson disease by fluorescent PCR. Arch Neurol. 2001 Nov; 58(11):1879-82.
Score: 0.001
-
Thalamic deep brain stimulation: effects on the nontarget limbs. Mov Disord. 2001 Nov; 16(6):1137-42.
Score: 0.001
-
Alcohol dehydrogenase polymorphism and Parkinson's disease. Neurosci Lett. 2001 Jun 01; 305(1):70-2.
Score: 0.001
-
Comparison of thalamotomy and pallidotomy for the treatment of dystonia. Neurosurgery. 2001 Apr; 48(4):818-24; discussion 824-6.
Score: 0.001
-
Thalamic deep brain stimulation: comparison between unilateral and bilateral placement. Arch Neurol. 2001 Feb; 58(2):218-22.
Score: 0.001
-
Long-term efficacy of posteroventral pallidotomy in the treatment of Parkinson's disease. Neurology. 2000 Oct 24; 55(8):1218-22.
Score: 0.001
-
Postural control in Parkinson's disease after unilateral posteroventral pallidotomy. Brain. 2000 Oct; 123 ( Pt 10):2141-9.
Score: 0.001
-
Neuropsychological outcome after unilateral pallidotomy for the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry. 2000 Sep; 69(3):326-36.
Score: 0.001
-
Variability and validity of polymorphism association studies in Parkinson's disease. Neurology. 2000 Aug 22; 55(4):533-8.
Score: 0.001
-
Polymorphism of NACP-Rep1 in Parkinson's disease: an etiologic link with essential tremor? Neurology. 2000 Mar 14; 54(5):1195-8.
Score: 0.001
-
Weight gain following unilateral pallidotomy in Parkinson's disease. Acta Neurol Scand. 2000 Feb; 101(2):79-84.
Score: 0.001
-
Bruxism in Huntington's disease. Mov Disord. 2000 Jan; 15(1):171-3.
Score: 0.001
-
The alpha-synuclein gene is not a major risk factor in familial Parkinson disease. Neurogenetics. 1999 Sep; 2(3):191-2.
Score: 0.001
-
Comparison of mouse bioassay and immunoprecipitation assay for botulinum toxin antibodies. J Neurol Neurosurg Psychiatry. 1999 May; 66(5):612-6.
Score: 0.001
-
Effects of cerebrospinal fluid from patients with Parkinson disease on dopaminergic cells. Arch Neurol. 1999 Feb; 56(2):194-200.
Score: 0.001
-
Multiple system atrophy: the putative causative role of environmental toxins. Arch Neurol. 1999 Jan; 56(1):90-4.
Score: 0.001
-
The G209A mutation in the alpha-synuclein gene is not detected in familial cases of Parkinson disease in non-Greek and/or Italian populations. Arch Neurol. 1998 Dec; 55(12):1521-3.
Score: 0.001
-
Unilateral thalamic deep brain stimulation for refractory essential tremor and Parkinson's disease tremor. Neurology. 1998 Oct; 51(4):1063-9.
Score: 0.001
-
Posteroventral medial pallidotomy for treatment of Parkinson's disease: preoperative magnetic resonance imaging features and clinical outcome. J Neurosurg. 1998 Aug; 89(2):194-9.
Score: 0.001
-
Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. Arch Neurol. 1998 Jul; 55(7):969-78.
Score: 0.001
-
Pallidotomy for generalized dystonia. Mov Disord. 1998 Jul; 13(4):693-8.
Score: 0.001
-
Assessment of motor function after stereotactic pallidotomy. Neurology. 1998 Jan; 50(1):266-70.
Score: 0.001
-
Variability of the immunologic and clinical response in dystonic patients immunoresistant to botulinum toxin injections. Mov Disord. 1998 Jan; 13(1):150-4.
Score: 0.001
-
Symptomatic and functional outcome of surgical treatment of cervical dystonia. J Neurol Neurosurg Psychiatry. 1997 Nov; 63(5):642-8.
Score: 0.001
-
Microelectrode-guided posteroventral pallidotomy for treatment of Parkinson's disease: postoperative magnetic resonance imaging analysis. J Neurosurg. 1997 Sep; 87(3):358-67.
Score: 0.001
-
Posteroventral medial pallidotomy in levodopa-unresponsive parkinsonism. Arch Neurol. 1997 Aug; 54(8):1026-9.
Score: 0.001
-
Molecular detection of new mutations, resolution of ambiguous results and complex genetic counseling issues in Huntington disease. Am J Med Genet. 1996 Dec 18; 66(3):281-6.
Score: 0.001
-
Botulinum toxin injection into vocal cord in the treatment of malignant coprolalia associated with Tourette's syndrome. Mov Disord. 1996 Jul; 11(4):431-3.
Score: 0.001
-
Ecstasy intoxication: an overlap between serotonin syndrome and neuroleptic malignant syndrome. Clin Neuropharmacol. 1996 Apr; 19(2):157-64.
Score: 0.001
-
Neurologic presentation of Wilson disease without Kayser-Fleischer rings. Neurology. 1996 Apr; 46(4):1040-3.
Score: 0.001
-
Neuropsychological functioning in cortical-basal ganglionic degeneration: Differentiation from Alzheimer's disease. Neurology. 1996 Mar; 46(3):720-6.
Score: 0.001
-
Outcome after stereotactic thalamotomy for dystonia and hemiballismus. Neurosurgery. 1995 Mar; 36(3):501-7; discussion 507-8.
Score: 0.001
-
Clozapine for acute and maintenance treatment of psychosis in Parkinson's disease. J Neuropsychiatry Clin Neurosci. 1995; 7(4):471-5.
Score: 0.001
-
A comparison of postspace-flight orthostatic intolerance to vasovagal syncope and autonomic failure and the potential use of the alpha agonist midodrine for these conditions. J Clin Pharmacol. 1994 May; 34(5):466-71.
Score: 0.001
-
Rett syndrome: controlled study of an oral opiate antagonist, naltrexone. Ann Neurol. 1994 Apr; 35(4):464-70.
Score: 0.001
-
9p monosomy in a patient with Gilles de la Tourette's syndrome. Neurology. 1991 Sep; 41(9):1513-5.
Score: 0.001
-
Intrathecal baclofen for intractable axial dystonia. Neurology. 1991 Jul; 41(7):1141-2.
Score: 0.001
-
Blepharospasm-oromandibular dystonia associated with a left cerebellopontine angle meningioma. J Emerg Med. 1990 Sep-Oct; 8(5):571-4.
Score: 0.001
-
Extrapyramidal involvement in Rett's syndrome. Neurology. 1990 Feb; 40(2):293-5.
Score: 0.001
-
Rett syndrome and associated movement disorders. Mov Disord. 1990; 5(3):195-202.
Score: 0.001